Malt1 tumor inhibitor, and drug containing same and use thereof

By inhibiting the binding region of MALT1 protein and BCL-10, non-competitive inhibitors targeting the MALT1 tumor effect region were developed, which solved the problem of poor treatment effect in solid tumors in the prior art and achieved the goal of multiple malignant tumors. Effective treatment.

WO2024245445A1PCT designated stage expired Publication Date: 2024-12-05XZYP (BEIJING) BIOTECH CO LTD
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2024/097119
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-06-01
Filing Date
2024-06-03
Publication Date
2024-12-05

AI Technical Summary

Technical Problem

Existing MALT1 inhibitors mainly target typical active central regions, and lack of research in solid tumors, making it difficult to effectively treat multiple types of malignant tumors.

Method used

By inhibiting the binding region between MALT1 protein and BCL-10, the formation of the CARMA3-BCL10-MALT1 complex was disrupted, and antisense oligonucleotides were used to intervene in the activity of MALT1 tumor effector region, and non-competitive MALT1 tumor inhibitors were developed. , able to intervene in the death domain of MALT1.

Benefits of technology

It has achieved effective treatment of a variety of cancers, including blood and solid cancers, especially in malignant tumors in the lungs, pancreas, liver, digestive tract and other areas, and has shown good therapeutic effects, and is also related to the existing Para-caspase activity. The combination of central inhibitors can improve the therapeutic effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PCTCN2024097119-FTAPPB-I100001
    Figure PCTCN2024097119-FTAPPB-I100001
  • Figure PCTCN2024097119-FTAPPB-I100002
    Figure PCTCN2024097119-FTAPPB-I100002
  • Figure PCTCN2024097119-FTAPPB-I100003
    Figure PCTCN2024097119-FTAPPB-I100003
Patent Text Reader

Abstract

Provided in the present invention is an MALT1 tumor inhibitor. The MALT1 tumor inhibitor can inhibit the expression of an MALT1 gene or inactivate the function of an MALT1 protein, and is selected from a preparation capable of influencing the expression of a death domain of the MALT1 protein, a preparation capable of knocking out a death domain, a preparation capable of changing a death domain structure or a preparation capable of degrading a death domain. The MALT1 tumor inhibitor can effectively treat various solid tumors, can treat tumors which cannot be treated by an immune checkpoint inhibitor, and can achieve a synergistic effect when being combined with an immune checkpoint inhibitor, therefore, the curative effect is significantly enhanced.
Need to check novelty before this filing date? Find Prior Art

Description

MALT1 tumor inhibitor, medicine containing same and application thereof Technical Field

[0001] The present application relates to the field of pharmaceutical biotechnology, and specifically discloses a MALT-1 tumor therapeutic reagent, drugs and other products containing the same, and the application of such products in the field of tumor treatment. Background Art

[0002] MALT1 is a cysteine-dependent aspartate-specific protease that has high homology with members of the Para-caspase family and plays a key role in the activation of the NF-κB signaling pathway.

[0003] The structure of MALT1 protein mainly consists of three parts: Para-caspase domain, death domain and immunoglobulin-like domain.

[0004] MALT1 can cleave multiple substrates, including CYLD, A20, and RelB, all of which are negative regulators of the NF-κB signaling pathway. Therefore, in addition to acting as a scaffold and participating in the formation of complexes in the NF-κB signaling pathway, MALT1 can also participate in and activate NF-κB through its proteolytic activity. Furthermore, MALT1 can induce growth in lymphocytes and stimulate the transcription of the cytokine interleukin-2, which participates in immune responses. Therefore, MALT1 inhibitors can effectively inhibit the intracellular activation of MALT1, which has important implications for MALT1-involved immune regulation and lymphoma treatment.

[0005] Studies have shown that MALT1 protein has been associated with hematological malignancies. Studies targeting MALT1 include:

[0006] Cornell University disclosed in patent document WO2014 / 074815 an aryl triazole compound (2-chloro-N-[4-[5-(3,4-dichlorophenyl)-3-(2-methoxyethoxy)-1H-1,2,4-triazol-1-yl]phenyl]acetamide (hereinafter referred to as MI-2) that inhibits MALT1 activity by binding to the para-caspase fragment. Subsequently, Cornell University disclosed a series of MI-2 derivatives in patent document WO2017 / 040304, the structures of which are shown in Figure 1. These compounds all covalently bind to the para-caspase fragment of MALT1 and can significantly inhibit the development of ABC-DLBCL tumors in in vitro and in vivo experiments.

[0007] Hatcher JM et al. disclosed a series of aryl triazole compounds (WO2014 / 074815). These compounds carry a reactive chloromethyl warhead and are proposed to covalently bind to the catalytic C464 in the para-aspase domain of MALT1, as shown in Figure 1.

[0008] Helmholtz Zentrum München disclosed in patent documents WO2013 / 017637, WO2014 / 086478, and WO2014 / 207067 a series of phenothiazine compounds and their derivatives as MALT1 inhibitors, including mepazine, promazine, and thioridazine (see Figure 2), showing that this type of MALT1 inhibitor has good biochemical and cellular activity.

[0009] Novartis disclosed a series of pyrazolopyrimidine derivatives as MALT1 inhibitors in patent documents WO2015 / 181747 and WO2017 / 081641, see Figure 3 .

[0010] Janssen disclosed a series of trifluoromethylpyrazoles as MALT1 inhibitors in patent documents WO2019 / 243965, US2019 / 0381012 and US2019 / 0381019, see Figure 4.

[0011] However, the above-mentioned MALT1 inhibitors all target the typical active center region of MALT1, namely the Para-caspase fragment; and there are few research reports on this type of MALT1 inhibitors in solid tumors.

[0012] In addition, General Medical disclosed a MALT1 inhibitor targeting the CARMA2,3-BCL10-MALT1 complex in patent document CN111770759A. The membrane-associated guanylate kinase protein (CARMA) containing the caspase recruitment domain is a member of the membrane-associated guanylate kinase family. The CARMA protein family has three members, namely CARMA1, CARMA2 and CARMA3. Among them, CARMA1 is mainly expressed in lymphoid tissues, including spleen, thymus and peripheral blood; CARMA2 is mainly expressed in the skin and mucous membranes, among which the level of skin is 5 times higher than that of other tissues and organs; CARMA3 is widely expressed in various organs and tissues such as the heart, kidney, and liver. Therefore, the CARMA2,3-BCL10-MALT1 complex disclosed in patent document CN111770759A only discloses that it plays a role in immune cells.

[0013] Summary of the Invention

[0014] The present application has found through experiments that by inhibiting the activity of the BCL10 and MALT1 binding region, the formation process of the CARMA3-BCL10-MALT1 complex (hereinafter referred to as the CBM complex) can be disrupted. Based on this, the present application has discovered for the first time that there is an effector region for tumor treatment in the MALT1 protein structure (hereinafter referred to as the MALT1 tumor effector region), which plays an important role in the protein-protein interaction between MALT1 and BCL-10. The MALT1 tumor effector region is different from the catalytic active center of the Para-caspase of MALT1, but is located in the death domain of MALT1.

[0015] The MALT1 tumor effector region has been experimentally validated as a target for tumor therapy. Therefore, the MALT1 tumor effector region, the base sequence expressing the death domain, and the protein-protein interaction site between MALT1 and BCL-10 can all serve as targets or sites with beneficial effects in tumor therapy. Intervention of the MALT1 tumor effector region, the base sequence expressing the death domain, and the protein-protein interaction site between MALT1 and BCL-10 can achieve a therapeutic effect on tumors.

[0016] Therefore, the present application provides an antisense oligonucleotide targeting the MALT1 tumor effector region, wherein the nucleotide sequence of the antisense oligonucleotide is shown in any one of SEQ ID Nos. 2 to 6 and 8 to 12.

[0017] Based on the MALT1 tumor effector region, the present application also proposes an inhibitor (hereinafter referred to as MALT1 tumor inhibitor) that can effectively treat tumors, especially solid tumors, by interacting with the MALT1 tumor effector region.

[0018] The MALT1 tumor effector region is located away from the catalytic active center of MALT1 Para-caspase. Therefore, the MALT1 tumor inhibitor and the MALT1 enzyme activity inhibitor have the characteristics of non-competitive inhibition and can be used in combination with existing inhibitors targeting the MALT1 Para-caspase active center to achieve better therapeutic effects.

[0019] Therefore, the present application provides a pharmaceutical composition comprising the MALT1 tumor inhibitor and a pharmaceutically acceptable carrier.

[0020] More importantly, unlike existing MALT1 inhibitors that are only effective in blood tumors, the MALT1 tumor inhibitor described in this application also has a good therapeutic effect on solid tumors, and there has never been a similar report in the prior art.

[0021] Therefore, the present application provides the use of the MALT1 tumor inhibitor and the pharmaceutical composition in preparing drugs for treating tumors.

[0022] In the present application, MALT1 tumor inhibitors that inhibit the activity of the MALT1 tumor effector region can be used to treat a variety of cancers, including blood cancers and solid cancers, especially including but not limited to malignant tumors occurring in the lungs, pancreas, liver, digestive tract, reproductive system, etc., such as Hodgkin's lymphoma, non-Hodgkin's lymphoma, lung cancer, breast cancer (including triple-negative breast cancer), melanoma, ovarian cancer, gastric cancer, colon cancer, rectal cancer, liver cancer, pancreatic cancer, head and neck malignancies, urinary system malignancies, endometrial cancer, cervical cancer, osteosarcoma, chondrosarcoma, Ewing's sarcoma, thyroid cancer, hepatoblastoma, Wilms' tumor, etc. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] FIG1 shows the structural formula of an aryl triazole compound covalently bound to the catalytic C464 in the paraaspase domain of MALT1;

[0024] FIG2 shows the structural formula of MALT1 inhibitors of phenothiazine compounds and their derivatives;

[0025] FIG3 shows the structural formula of MALT1 inhibitors of pyrazolopyrimidine derivatives;

[0026] FIG4 shows the structural formula of trifluoromethylpyrazole MALT1 inhibitor;

[0027] Figure 5 shows the antisense oligonucleotide sequences in E0771 cells using Lipofectamine TM Western blot results 48 hours after transfection with 3000 reagent, where 5 μL of Lipofectamine was added to each well of a 12-well plate. TM 3000 reagents;

[0028] Figure 6 shows the tumor growth curves corresponding to mutants at different sites of the MALT1 death structure;

[0029] Figure 7 shows the Western Blot results of 11 cell lines after immunoprecipitation.

[0030] FIG8 shows the survival rate of tumor cells in 11 cell lines before and after the addition of macrophages;

[0031] FIG9 shows the corresponding relationship between the mutants at different sites of the MALT1 death structure and the number of macrophages;

[0032] FIG10 shows the visualization results of cell number obtained by direct photography under a microscope;

[0033] FIG11 shows: a single parameter histogram of flow cytometry results;

[0034] FIG12 shows the corresponding relationship between the mutants at different sites of the MALT1 death structure and the macrophage ratio, CD206 intensity (M2 marker) and MHCI intensity (M1 marker);

[0035] FIG13 shows the tumor immune cell infiltration in each mouse as detected by flow cytometry;

[0036] FIG14 shows the corresponding relationship between target mutation cell lines and tumor volumes;

[0037] FIG15 shows the flow cytometry experimental results of verifying the transformation of macrophages from M2 macrophages to M1 macrophages;

[0038] FIG16 shows: B16F10-MALT1-KD cells (melanoma cells) were supplemented with VEC, M-WT, M-WT-C83A, M-WT-V87R, M-WT-L88D, and M-WT-E104R (respectively marked from top to bottom on the right side of FIG16 ) to obtain the corresponding cell lines, and then 1×10 5 The corresponding cells were subcutaneously injected into the subcutaneous tissue near the groin of wild-type mice, and the tumor size on day 18 is shown;

[0039] FIG17 shows: E0771-MALT1-KD cells (breast cancer cells) were supplemented with VEC, M-WT, M-WT-C83A, M-WT-V87R, M-WT-L88D, and M-WT-E104R (respectively marked from top to bottom on the right side of FIG17 ) to obtain the corresponding cell lines, and then 1×10 5 The corresponding cells were orthotopically injected into the fat pad of wild-type mice, and the tumor size on day 19 is shown;

[0040] FIG18 shows that the antisense oligonucleotide prodrug can significantly inhibit the further development of cancer cells, as verified in breast cancer cells E0771;

[0041] Figure 19 shows: B16F10-CTRL, B16F10-MALT1-KD1, B16F10-MALT1-KD2 were respectively + T cells were co-cultured, and luciferase activity was measured 24 hours later to evaluate the survival rate of tumor cells. The results are shown in Figure 19A, and the tumor volume change curve in the animal model is shown in Figure 19B;

[0042] Figure 20 shows: MC38-CTRL, MC38-MALT1-KD1, MC38-MALT1-KD2 were respectively + T cells were co-cultured, and luciferase activity was measured 24 hours later to evaluate the survival rate of tumor cells. The results are shown in Figure 20A, and the tumor volume change curve in the animal model is shown in Figure 20B;

[0043] FIG21 shows the results of the validation of the survival rate of mouse breast cancer E0771 cells, see FIG21A and FIG21B ;

[0044] FIG. 22 shows the results of the validation of the survival rate of mouse melanoma B16F10 cells, see FIG. 22A and FIG. 22B . DETAILED DESCRIPTION

[0045] Terms and Definitions

[0046] “NCBI Gene ID” and “NCBI NP” are provided by the National Center for Biotechnology Information (NCBI), available at https: / / www.ncbi.nlm.nih.gov / .

[0047] "MALT1 gene" NCBI Gene ID: 10892, which encodes a caspase-like protease that plays a role in BCL10-induced NF-κB activation. This protein is a component of the CARMA3-BCL10-MALT1 (CBM) signalosome, which can trigger NF-κB signaling and lymphocyte activation after antigen-receptor stimulation. MALT1 may refer to human MALT1, including naturally occurring variants, molecules, and alleles thereof. MALT1 may also refer to MALT1 of mammals such as mice, rats, rabbits, dogs, cats, cattle, horses, and pigs.

[0048] The "CARMA3-BCL10-MALT1 signalosome complex" refers to a three-molecule protein complex composed of protein 3 containing CARD and membrane-associated guanylate kinase-like domains (i.e., CARMA3), B-cell lymphoma / leukemia factor 10 (BCL10), and mucosa-associated lymphoid tissue lymphoma translocation protein 1, i.e., composed of CARMA3, BCL10, and MALT1. After antigen-receptor binding and signal cascade transduction, CARMA3 is released from the autoinhibitory conformation and binds to BCL10 and MALT1 to form a functional CARMA2,3-BCL10-MALT1 complex.

[0049] "Inhibiting the activity of the CARMA2,3-BCL10-MALT1 complex" refers to the formation, function, or expression level of the CARMA2,3-BCL10-MALT1 complex. In some embodiments, the activity is the level of formation of the CARMA2,3-BCL10-MALT1 complex. In some embodiments, to inhibit the activity of the CARMA2,3-BCL10-MALT1 complex, a MALT1 tumor inhibitor that inhibits the activity of the CARMA2,3-BCL10-MALT1 complex is administered to the subject.

[0050] In some embodiments, the MALT1 tumor inhibitor can inhibit the activity of the CARMA2,3-BCL10-MALT1 complex by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 99% or more compared to a control level. A control level can be, for example, the activity of the CARMA2,3-BCL10-MALT1 complex before administration of the MALT1 tumor inhibitor, or the activity of the CARMA2,3-BCL10-MALT1 complex in cells that have not been treated (e.g., contacted) with the MALT1 tumor inhibitor.

[0051] In some embodiments, the MALT1 tumor inhibitor inhibits the activity of the CARMA2,3-BCL10-MALT1 complex in T cells, or inhibits the activity of the CARMA2,3-BCL10-MALT1 complex in tumor cells. In some embodiments, the tumor cells are tumor-infiltrating tumor cells. In some embodiments, the MALT1 tumor inhibitor reduces the amount of intact CARMA2,3-BCL10-MALT1 complex, as measured by the amount of intact complex in the cell, by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 99%, or more compared to a control level.

[0052] In some embodiments, the MALT1 tumor suppressors described herein inhibit complex formation. The MALT1 tumor suppressors can inhibit complex formation by binding to and inhibiting binding sites within the complex required for higher-order assembly (e.g., the MALT1 binding site on BCL10). In some embodiments, the MALT1 tumor suppressors can inhibit the release of CARMA3 from its autoinhibitory conformation. In some embodiments, the MALT1 tumor suppressors inhibit upstream factors required for CARMA2,3-BCL10-MALT1 complex formation.

[0053] In some embodiments, the MALT1 tumor inhibitor can reduce the expression level of at least one component of the CARMA2,3-BCL10-MALT1 complex by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 99% or more compared to a control level. The control level can be, for example, the expression level of at least one component (e.g., CARMA3, BCL10, or MALT1) before administration of the MALT1 tumor inhibitor. One skilled in the art can assess the integrity of the complex using, for example, co-immunoprecipitation or sucrose gradient analysis to determine whether the MALT1 tumor inhibitor effectively inhibits the formation of the CARMA2,3-BCL10-MALT1 complex. For a given component, one skilled in the art can perform PCR-based analysis or western blotting to assess mRNA levels or protein levels, respectively, to determine whether the level of at least one component in the complex is reduced.

[0054] In some embodiments, the activity is a function of the CARMA2,3-BCL10-MALT1 complex. In some embodiments, the MALT1 tumor inhibitor inhibits the CARMA2,3-BCL10-MALT1 complex from activating its downstream targets (e.g., NF-κB nuclear translocation and activation).

[0055] In some embodiments, the MALT1 tumor inhibitor reduces MALT1 Para-caspase activity by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 99% or more compared to a control level. The control level can be, for example, the MALT1 Para-caspase activity prior to administration of the MALT1 inhibitor.

[0056] In some embodiments, the MALT1 tumor inhibitor inhibits interaction with a MALT1 substrate or activation of a MALT1 substrate by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 99% or more. A control level can be, for example, the interaction with a MALT1 substrate or activation of a MALT1 substrate prior to administration of the MALT1 tumor inhibitor.

[0057] In some embodiments, the MALT1 tumor inhibitor reduces cleavage of a MALT1 substrate by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 99% or more. A control level can be, for example, cleavage of a MALT1 substrate prior to administration of the MALT1 tumor inhibitor.

[0058] In some embodiments, the MALT1 tumor inhibitor reduces the monoubiquitination of MALT1 by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 99% or more. The control level can be, for example, the monoubiquitination of MALT1 before administration of the MALT1 tumor inhibitor. One skilled in the art will be able to determine whether a MALT1 tumor inhibitor effectively inhibits activation of downstream targets using standard assays (e.g., using immunofluorescence to detect nuclear NF-κB).

[0059] In some embodiments, the activity is the expression level of the CARMA2,3-BCL10-MALT1 complex.

[0060] In some embodiments, the MALT1 tumor inhibitor reduces the expression level of the CARMA2,3-BCL10-MALT1 complex by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 99% or more compared to a control level. The control level can be, for example, the level of the CARMA2,3-BCL10-MALT1 complex prior to administration of the MALT1 tumor inhibitor.

[0061] In some embodiments, the MALT1 tumor inhibitor reduces the expression level of at least one gene selected from the group consisting of the CARMA3 gene, the BCL10 gene, and the MALT1 gene by 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 99%, or more, compared to a control level. The control level can be, for example, the level of expression of the CARMA3 gene, the BCL10 gene, or the MALT1 gene before administration of the MALT1 tumor inhibitor. Methods known in the art can be used to determine whether a MALT1 tumor inhibitor reduces the expression level of a gene (e.g., by a PCR-based assay) or a gene product (e.g., by western blot).

[0062] "Tumor antigens" refer to antigens that are differentially expressed by cancer cells and can therefore be used to target cancer cells. Tumor antigens are antigens that can potentially stimulate a significant tumor-specific immune response. Although not necessarily expressed, some of these antigens are encoded by normal cells. These antigens can be characterized as: antigens that are usually silent (i.e., not expressed) in normal cells; antigens that are only expressed at a specific stage of differentiation; and antigens that are transiently expressed (such as embryonic and fetal antigens). Other tumor antigens are encoded by mutated cellular genes, such as oncogenes (e.g., activated ras oncogenes), suppressor genes (e.g., mutated p53), and fusion proteins produced by internal deletions or chromosomal translocations. Other tumor antigens can also be encoded by viral genes, such as genes carried on RNA and DNA tumor viruses. Many tumor antigens have been identified for various solid tumors: MAGE1, MAGE2, and MAGE3, identified by immunology; MART-1 / Melan-A, gp100, carcinoembryonic antigen (CEA), HER2, mucins (i.e., MUC-1), prostate-specific antigen (PSA), and prostatic acid phosphatase (PAP). In addition, viral proteins, such as those encoded by hepatitis B virus (HBV), Epstein-Barr virus (EBV), and human papillomavirus (HPV), have been shown to be important in the development of hepatocellular carcinoma, lymphoma, and cervical cancer, respectively.

[0063] "Engineering" and its equivalents refer to one or more artificially designed changes in nucleic acids. In some embodiments, engineering can refer to the alteration, addition and / or deletion of genes.

[0064] An "engineered cell" may refer to a cell that has added, deleted, and / or altered genes.

[0065] "Cell" or "engineered cell" and equivalents may refer to cells of human or non-human animal origin.

[0066] "Polypeptide" refers to a polymer of amino acids.

[0067] "Protein" and "polypeptide" are used interchangeably in this application. Peptides are relatively short polypeptides, typically about 2 to 60 amino acids in length. The polypeptides used in this application typically contain amino acids such as the 20 most common L-amino acids in proteins. However, other amino acids and / or amino acid analogs known in the art may be used. One or more amino acids in a polypeptide may be modified, for example, by adding chemical entities (e.g., carbohydrate groups; phosphate groups; fatty acid groups; linkers for conjugation, functionalization, etc.). A polypeptide having a non-polypeptide portion covalently or non-covalently associated therewith is still considered a "polypeptide." Exemplary modifications include glycosylation and palmitoylation. Polypeptides can be purified from natural sources, produced using recombinant DNA technology, or synthesized by chemical means (e.g., conventional solid phase peptide synthesis), etc.

[0068] "Polypeptide sequence" or "amino acid sequence" may refer to the polypeptide material itself and / or sequence information that biochemically characterizes the polypeptide (i.e., the consecutive letters or three-letter codes used as abbreviations for the amino acid names). Unless otherwise indicated, polypeptide sequences presented herein are presented in an N-terminal to C-terminal direction.

[0069] In some embodiments, a nucleic acid encoding a polypeptide described herein (eg, an inhibitory polypeptide) is contained in a vector.

[0070] In some embodiments, the nucleic acid sequence encoding a given polypeptide or any module thereof described herein is operably linked to a vector.

[0071] "Vector" refers to a nucleic acid construct designed for delivery to a host cell or for transfer between different host cells. The vectors used in this application can be viral or non-viral.

[0072] "Vector" encompasses any genetic element that is capable of replication and transfer of gene sequences to cells when associated with appropriate control elements. Vectors may include, but are not limited to, cloning vectors, expression vectors, plasmids, phages, transposons, cosmids, artificial chromosomes, viruses, virions, and the like.

[0073] "Expression vector" refers to a vector that directs the expression of RNA or polypeptides from a sequence linked to a transcriptional regulatory sequence. The expressed sequence is typically, but not necessarily, heterologous to the cell. An expression vector may contain additional elements, for example, an expression vector may have two replication systems, thereby allowing it to be maintained in two organisms, for example, in human cells for expression and in prokaryotic hosts for cloning and amplification.

[0074] "Expression" refers to the cellular processes involved in the production of RNA and protein, and secretion of protein when appropriate, including, but not limited to, e.g., transcription, transcript processing, translation, and protein folding, modification, and processing, as applicable.

[0075] "Expression products" include RNA transcribed from a gene and polypeptides obtained by translation of mRNA transcribed from a gene.

[0076] "Gene" refers to a nucleic acid sequence that is transcribed (DNA) into RNA in vitro or in vivo when operably linked to appropriate regulatory sequences. A gene may or may not include regions preceding and following the coding region, such as a 5' untranslated (5'UTR) sequence or "leader" sequence and a 3'UTR sequence or "trailer" sequence, as well as intervening sequences (introns) between the individual coding segments (exons).

[0077] The "tumor effector region" in the present invention refers to a continuous sequence of the MALT-1 death domain, approximately from the 64th amino acid residue to the 114th amino acid residue at the N-terminus of MALT-1. This region is a key structure for binding to BCL-10 and forming the CARMA3-BCL10-MALT1 complex, thereby activating downstream pathways. By structurally altering this tumor effector region, the function of the MALT-1 protein can be inactivated, thereby inhibiting or treating tumors.

[0078] "MALT1 tumor suppressor" herein refers to an agent that inhibits the expression of the MALT-1 tumor effector region at the nucleic acid level or inactivates its activity at the protein level. In some embodiments, the MALT-1 tumor suppressor can be a nucleic acid that inhibits the expression of the MALT-1 death domain: siRNA, shRNA, ASO, double-stranded nucleic acid. In other embodiments, the MALT-1 tumor suppressor can be an agent that mutates the site on the tumor effector region / death domain that binds to BCL10. The MALT-1 tumor suppressor can also be an agent that homologously recombines a gene fragment encoding a site on the tumor effector region / death domain that binds to BCL10. In other embodiments, the MALT-1 tumor suppressor can also be an agent that degrades the MALT-1 protein, such as a PROTAC or molecular glue.

[0079] "MALT1 enzyme activity inhibitors" herein refer to inhibitors targeting the para-caspase domain. It is known that the constitutive activity of the MALT1 protease drives the survival and proliferation of various lymphoid malignancies. Therefore, MALT1 enzyme activity inhibitors can effectively inhibit tumor survival and growth. In some embodiments, the MALT1 enzyme activity inhibitor is a small molecule inhibitor having structural formulas 1-47 herein.

[0080] "Antisense oligonucleotides" are oligonucleotides that inhibit gene expression by sequence-specifically hybridizing to a continuous sequence on the target gene's DNA or mRNA. They are molecular drugs that regulate gene expression at the gene level and are between 5 and 40 nucleotides in length. The antisense oligonucleotides of the present invention are single-stranded.

[0081] A "nucleotide" is a building block of an oligonucleotide, such as a DNA or RNA nucleotide, which consists of a ribose sugar moiety, a nucleobase moiety, and one or more phosphate groups.

[0082] "Modified nucleoside" is a bond other than a nucleic acid diester bond, by which two nucleosides are covalently coupled together. The oligonucleotides of the present invention may comprise a modified internucleoside bond. In some embodiments, the modified internucleoside bond increases the nuclease resistance of the oligonucleotide compared to a phosphodiester bond. The modified internucleoside bond is particularly useful for stabilizing oligonucleotides for in vivo use, and can protect against nuclease shearing in the DNA nucleoside or RNA nucleoside regions (e.g., inside the gap region of a gapmer oligonucleotide) in the oligonucleotide and in the modified nucleoside regions.

[0083] "Homology" refers to the degree of similarity between the nucleotide sequences of two nucleic acid molecules or the amino acid sequences of two protein molecules in the study of molecular evolution.

[0084] A "pharmaceutical composition" refers to an active agent in combination with a pharmaceutically acceptable carrier, such as those commonly used in the pharmaceutical industry.

[0085] The "reagent" may be in the form of a salt (e.g., with an organic or inorganic acid). Examples of suitable acids for forming such acid addition salts include trifluoroacetic acid, hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, acetic acid, citric acid, oxalic acid, malonic acid, salicylic acid, p-aminosalicylic acid, malic acid, fumaric acid, succinic acid, ascorbic acid, maleic acid, sulfonic acid, phosphonic acid, perchloric acid, nitric acid, formic acid, propionic acid, gluconic acid, lactic acid, tartaric acid, hydroxymaleic acid, pyruvic acid, phenylacetic acid, benzoic acid, p-aminobenzoic acid, p-hydroxybenzoic acid, methanesulfonic acid, acetic acid, benzoic ... Alkanesulfonic acid, nitrous acid, hydroxyethanesulfonic acid, ethylenesulfonic acid, p-toluenesulfonic acid, naphthalenesulfonic acid, sulfanilic acid (sulfanilic acid), camphorsulfonic acid, china acid, mandelic acid, o-methylmandelic acid, hydrogen-benzenesulfonic acid, picric acid, adipic acid, d-o-tolyltartaric acid, tartronic acid, (o, m, p) toluic acid, naphthylaminesulfonic acid and other mineral acids or carboxylic acids well known in the art. Salts are prepared by contacting the free base form with a sufficient amount of the desired acid to produce the salt in a conventional manner.

[0086] "Pharmaceutically acceptable" refers to the following compounds, materials, compositions and / or dosage forms: within the scope of sound medical judgment, suitable for contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response or other problems or complications, and commensurate with a reasonable benefit / risk ratio.

[0087] In some embodiments, the pharmaceutically acceptable carrier may be a carrier other than water.

[0088] In some embodiments, a pharmaceutically acceptable carrier can be an artificial carrier or an engineered carrier, for example, a carrier in which the active ingredient is not found in nature.

[0089] "Administration" refers to placing a therapeutic agent (e.g., an agent) or pharmaceutical composition disclosed herein in a subject by a method or route that allows the agent to be at least partially delivered to a desired site. Pharmaceutical compositions containing agents disclosed herein can be administered by any appropriate route that produces an effective treatment in a subject.

[0090] In some embodiments, administration is systemic administration.

[0091] "Systemic administration" refers to a route of administration of an agent into the circulatory system of a subject. In some embodiments, administration is local administration.

[0092] "Local administration" refers to administering an agent to the site of action (eg, a tumor). Local administration may be desirable to avoid adverse side effects caused by systemic administration of a therapeutic agent or pharmaceutical composition.

[0093] "Administering / administering in combination" refers to the delivery of two (or more) different therapies to a subject while the subject is afflicted with a disorder, e.g., the delivery of two or more therapies after the subject has been diagnosed with a disorder or disease (e.g., a tumor) and before the disorder is cured or eliminated or the treatment is stopped for other reasons.

[0094] A "unit dosage form" refers to a dosage suitable for a single administration. For example, a unit dosage form can be an amount of therapeutic agent disposed in a delivery device, such as a syringe or an intravenous drip bag.

[0095] In some embodiments, the unit dosage form is administered as a single administration.

[0096] In some embodiments, more than one unit dosage form may be administered simultaneously.

[0097] An "effective amount" refers to the amount of an agent required to alleviate at least one symptom of a tumor (e.g., a headache). Thus, the term "therapeutically effective amount" refers to the amount of an agent sufficient to provide a specific anti-cancer effect when administered to a typical subject. As used herein, an effective amount will also include an amount of an agent sufficient to delay the development of tumor symptoms, alter the course of tumor symptoms (e.g., but not limited to, slowing the progression of a tumor), or reverse tumor symptoms. Therefore, specifying an exact "effective amount" is generally not practical. However, for any given situation, an appropriate "effective amount" can be determined by one of ordinary skill in the art using only routine experimentation. Effective amount, toxicity, and therapeutic efficacy can be evaluated by standard pharmaceutical procedures in cell culture or experimental animals. The dosage may vary depending on the dosage form employed and the route of administration used. The dose ratio between the toxic effect and the therapeutic effect is the therapeutic index and can be expressed as the ratio LD50 / ED50. Compositions and methods that exhibit a high therapeutic index are preferred.

[0098] A "therapeutically effective dose" can be initially estimated from cell culture assays. In addition, the dose can be formulated in an animal model to achieve a circulating plasma concentration range that includes the IC50 determined in cell culture or in an appropriate animal model. Levels in plasma can be measured, for example, by high performance liquid chromatography. The effect of any particular dose can be monitored by suitable bioassays (e.g., non-invasive imaging), etc. The dose can be determined by a physician and adjusted, if necessary, to suit the observed therapeutic effect.

[0099] "Statistically significant" or "significantly" refers to statistical significance and generally refers to a difference of 2 standard deviations (2SD) or greater. Except in the operating examples, or where otherwise indicated, all numbers used herein expressing amounts of ingredients or reaction conditions are to be understood as being modified in all instances by the term "about."

[0100] "Effective treatment / efficacy": The efficacy of a MALT1 tumor inhibitor that inhibits the activity of the CARMA3-BCL10-MALT1 complex described herein, for example, in treating a condition described herein (e.g., a solid tumor) or inducing a response described herein (e.g., a reduction in tumor size) can be determined by a skilled clinician. However, treatment according to the methods described herein is considered "effective treatment" as the term is used herein if, following treatment according to the methods described herein, one or more signs or symptoms of a condition described herein are altered in a beneficial manner, other clinically acceptable symptoms are improved or even alleviated, or at least 10% of a desired response is induced. Efficacy can be assessed, for example, by measuring markers, indicators, symptoms, and / or the incidence of a condition treated according to the methods described herein, or any other suitable measurable parameter. Treatment according to the methods described herein can reduce the level of a symptom or marker of a condition by, for example, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% or more. The efficacy described herein can also be measured by failure of an individual to deteriorate or no longer require medical intervention (ie, cessation of disease progression) as assessed by hospitalization. Methods for measuring these indicators are known to those skilled in the art and / or described herein.

[0101] “About” when used with a percentage can mean ±1%.

[0102] "Includes / comprising" indicates that additional elements may be present in addition to the specified elements. The use of "includes / comprising" indicates inclusion rather than limitation.

[0103] "Consisting of" refers to the compositions, methods, and their respective components as described herein, excluding any elements not recited in the description of that embodiment.

[0104] "Consisting essentially of refers to the elements required for a given embodiment. The term permits the presence of additional elements that do not materially affect the basic and novel or functional characteristics of that embodiment of the technology.

[0105] "Reducing tumor symptoms" means improving any condition or symptom associated with a tumor. Such a reduction is at least 5%, 10%, 20%, 40%, 50%, 60%, 80%, 90%, 95%, 99% or more compared to an equivalent untreated control, as measured by any standard technique known to those skilled in the art. Various methods for administering the agents described herein to a subject are known to those skilled in the art.

[0106] Unless the context clearly indicates otherwise, "a / the" includes plural referents. Similarly, the word "or" is intended to include "and / and" unless the context clearly indicates otherwise.

[0107] Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below.The abbreviation "eg," derived from the Latin for example, is used herein to indicate non-limiting examples.

[0108] Additional terms are defined in the following description of various aspects and implementations of the technology.

[0109] The present invention provides a MALT1 tumor inhibitor, which can inhibit the expression of the MALT1 gene or inactivate the function of the MALT1 protein; the MALT1 tumor inhibitor is selected from a preparation that can affect the expression of the death domain of the MALT1 protein, a preparation that knocks out the death domain, a preparation that changes the structure of the death domain, or a preparation that degrades the death domain.

[0110] The antisense oligonucleotides of the present invention are useful for treating or in the preparation of a medicament for treating diseases mediated by the MALT1 protein. Human mucosa-associated lymphoid tissue protein 1 (MALT1), also known as human paracaspase-I (HsPCA-I), is a protease that was discovered from the genomic translocation t(11;18)(q21;q21), a recurrent rearrangement in MALT lymphomas that results in the production of the oncogenic fusion protein API2-MALT1. The MALT1 protein is a multidomain protein that includes an N-terminal death domain (DD) and two immunoglobulin (Ig1 / 2) domains, followed by a paracalcineurin (PCASP) and a C-terminal Ig3 domain. Constitutive activity of the MALT1 protease has been found to drive the survival and proliferation of various lymphoid malignancies. As previously mentioned, the frequent translocation t(11;18)(q21;q21) leads to the expression of the API2-MALT1 fusion protein in MALT lymphomas, rendering the MALT1 protease constitutively active, thereby enhancing anti-apoptotic NF-κB activation in lymphoma tumor cells. Furthermore, it is a hallmark of many malignant B-cell lymphomas, including diffuse large B-cell lymphoma (DLBCL) of the activated B-cell (ABC) type. ABC-type DLBCL cells are strictly dependent on chronic BCR signaling for survival and proliferation, which is frequently triggered by oncogenic driver mutations in the BCR adaptor protein CD79A and the B or CBM subunit CARD11. Indeed, the irreversible tetrapeptide MALT1 inhibitor zVRPR-FMK induces toxicity in ABC DLBCL cells, whereas other lymphomas, including germline center B-cell (GCB)-type DLBCL cells that are independent of BCR signaling, are insensitive to this MALT1 suicide inhibitor. In addition, inhibition of the MALT1 protease has been identified as a target for BCR-dependent somatic cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL). The Bruton's tyrosine kinase (BTK) inhibitor ibrutinib has been approved for the treatment of these lymphomas, but primary and secondary drug resistance emphasizes the need for alternative or combination treatment options. The MALT1 protease acts downstream of BTK and all known oncogenic events.

[0111] Outside the lymphatic system, MALT1 is involved in regulating innate immune responses, growth factor activation, or pro-inflammatory pathways in different cell types by coupling with different CARMA / CARD scaffold proteins. Therefore, MALT1 is thought to promote the growth and survival of certain tumors that rely on these pathways, including glioblastoma, breast cancer, or melanoma.

[0112] Because MALT-1 is a key mediator of the NFκB signaling pathway, it may be a useful drug target for a variety of diseases and conditions. The role of the MALT1 protease in generating adaptive immune responses has prompted research into whether MALT1 inactivation can ameliorate excessive immune responses in autoimmune and inflammatory diseases. Genetic inactivation of MALT1 protease function can prevent the development of experimental autoimmune encephalomyelitis (EAE), a mouse model of multiple sclerosis (MS). Furthermore, MALT1 protease has been implicated as a potential drug target for other autoimmune and inflammatory diseases, including rheumatoid arthritis, psoriasis, Sjögren's syndrome, systemic lupus erythematosus, vasculitic conditions, arthritis, and colitis.

[0113] Although the MALT1 protease plays a role in activating conventional T cells, its activity is crucial for the development and function of immunosuppressive Treg cells. The development of multi-organ inflammation in mice deficient in MALT1 paraprotease activation suggests that the loss of Treg cells tilts the immune system toward destructive autoinflammation, a potential drawback of MALT1 protease inactivation. On the other hand, the impairment of Treg cell function by MALT1 inhibition is thought to have the potential to enhance anti-tumor immunity in solid cancers.

[0114] This application discloses for the first time another target region of MALT1 protein that is different from Para-caspase - a novel target region - MALT1 tumor effector region.

[0115] This application demonstrates for the first time that the MALT1 tumor effector region, located in the death domain of MALT1, is a tumor target region distinct from para-caspase. Inhibiting the activity of the MALT1 tumor effector region can be used to treat solid tumors.

[0116] The MALT1 tumor effector region is not adjacent to the para-caspase fragment of MALT1. Therefore, the MALT1 tumor inhibitor has a non-competitive advantage over inhibitors targeting the para-caspase fragment. Therefore, the MALT1 tumor inhibitor of the present application can be used in combination with existing MALT1 inhibitors targeting the MALT1 para-caspase active site to achieve better therapeutic effects.

[0117] As certain embodiments of the present invention, the MALT1 tumor inhibitor targets the interaction site between MALT1 and BCL-10, thereby reducing or eliminating the binding ability of MALT1 to BCL-10.

[0118] As certain embodiments of the present invention, the MALT1 tumor inhibitor can also inhibit MALT1 enzyme activity.

[0119] In certain embodiments of the present invention, the MALT1 tumor inhibitor acts on at least amino acid residues 64 to 114 based on the MALT1 amino acid sequence shown in SEQ ID No. 1, or a nucleotide sequence encoding the same.

[0120] The MALT1 protein sequence can have ≥75% homology with the amino acid sequence shown in SEQ ID No. 1, for example, it can be 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% homology.

[0121] In certain embodiments of the present invention, the MALT1 tumor inhibitor acts on at least positions 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87 of the death domain based on the MALT1 amino acid sequence. 109, 110, 111, 112, 113, or / and 114 amino acid residue, or a nucleotide sequence encoding the same.

[0122] In certain embodiments of the present invention, the MALT1 tumor inhibitor acts on at least the 81st and / or 82nd amino acid residues based on the MALT1 amino acid sequence shown in SEQ ID No. 1, or the corresponding codons in the nucleotide sequence encoding the same.

[0123] As certain embodiments of the present invention, the MALT1 tumor suppressor includes an agent that inhibits, blocks or disrupts the protein-protein interaction between MALT1 and BCL10.

[0124] As certain embodiments of the present invention, the agent that inhibits, hinders or destroys the protein-protein interaction between MALT1 and BCL10 is selected from a covalent cross-linker that binds to the MALT1 death domain, a polyclonal antibody against the MALT1 death domain, or a monoclonal antibody against the MALT1 death domain, a small molecule inhibitor that inhibits the protein-protein interaction between MALT1 and BCL10, or an agent that point-mutates the binding site between the MALT-1 death domain and the BCL10, or an agent that eliminates the binding site between the MALT-1 death domain and the BCL10 by homologous recombination or gene editing.

[0125] In certain embodiments of the present invention, the covalent cross-linker that binds to the MALT1 death domain is selected from antioxidants, nonsteroidal anti-inflammatory drugs (NSAIDs), natural compounds, proteasome inhibitors, IKK inhibitors, NF-κB-specific antisense oligonucleotides, or cell-penetrating peptides.

[0126] As certain embodiments of the present invention, the antioxidant comprises alanolactone, N-acetyl-cysteine ​​((N-acetyl-cysteine)NAC)).

[0127] In certain embodiments of the present invention, the nonsteroidal anti-inflammatory drug (NSAID) comprises cyclooxygenase-2 (COX-2).

[0128] As certain embodiments of the present invention, the natural compounds include cymbopogon zizanioides, curcumin, ursolic acid, and resveratrol.

[0129] As certain embodiments of the present invention, the proteasome inhibitor includes the proteasome inhibitor PS341, melatonin.

[0130] In certain embodiments of the present invention, the IKK inhibitor is the tumor suppressor protein phosphatase PHLPP2.

[0131] As certain embodiments of the present invention, the cell-penetrating peptide comprises the cell-penetrating peptide inhibitor SN50.

[0132] As certain embodiments of the present invention, the mutators of the protein-protein interaction site between MALT1 and BCL10 include: reagents for performing point mutations on amino acid residues 81 and / or 82 of the MALT1 death domain, CRISPR-Cas9 gene shearing reagents, and reagents for performing homologous recombination on the protein-protein interaction site between MALT1 and BCL10.

[0133] As certain embodiments of the present invention, the MALT1 tumor inhibitor changes the microenvironment of tumor tissue, significantly reduces the number of macrophages in tumor tissue, and converts the macrophages in tumor tissue from M2 to M1.

[0134] In certain embodiments of the present invention, the MALT1 tumor suppressor is an antisense oligonucleotide that inactivates MALT1.

[0135] As certain embodiments of the present invention, the nucleotide sequence of the antisense oligonucleotide is shown in any one of SEQ ID Nos. 2-6 and 8-12.

[0136] The nucleotide sequence of the antisense oligonucleotide may have ≥90% homology with the nucleotide sequence shown in SEQ ID No. 2, for example, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% homology.

[0137] The nucleotide sequence of the antisense oligonucleotide may have ≥90% homology with the nucleotide sequence shown in SEQ ID No. 3, for example, it may be 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% homology.

[0138] The nucleotide sequence of the antisense oligonucleotide may have ≥90% homology with the nucleotide sequence shown in SEQ ID No. 4, for example, it may be 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% homology.

[0139] The nucleotide sequence of the antisense oligonucleotide may have ≥90% homology with the nucleotide sequence shown in SEQ ID No. 5, for example, it may be 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% homology.

[0140] The nucleotide sequence of the antisense oligonucleotide may have ≥90% homology with the nucleotide sequence shown in SEQ ID No. 6, for example, it may be 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% homology.

[0141] The nucleotide sequence of the antisense oligonucleotide may have ≥90% homology with the nucleotide sequence shown in SEQ ID No. 8, for example, it may be 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% homology.

[0142] The nucleotide sequence of the antisense oligonucleotide may have ≥90% homology with the nucleotide sequence shown in SEQ ID No. 9, for example, it may be 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% homology.

[0143] The nucleotide sequence of the antisense oligonucleotide may have ≥90% homology with the nucleotide sequence shown in SEQ ID No. 10, for example, it may be 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% homology.

[0144] The nucleotide sequence of the antisense oligonucleotide may have ≥90% homology with the nucleotide sequence shown in SEQ ID No. 11, for example, it may be 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% homology.

[0145] The nucleotide sequence of the antisense oligonucleotide may have ≥90% homology with the nucleotide sequence shown in SEQ ID No. 12, for example, it may be 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% homology.

[0146] As certain embodiments of the present invention, the nucleotide sequence of the antisense oligonucleotide is shown in any one of SEQ ID No. 2-3.

[0147] As certain embodiments of the present invention, the MALT1 tumor inhibitor that degrades the MALT1 death domain is selected from agents of the PROTAC, molecular glue, LYTAC, MoDE, ATAC, Apt-LYTAC, AbTAC, PROTAB, REULR, KineTAC, IFLD, ATTEC, AUTAC or AUTOTAC pathways.

[0148] The present invention provides a pharmaceutical composition comprising an effective amount of the MALT1 tumor inhibitor and a pharmaceutically acceptable carrier.

[0149] As certain embodiments of the present invention, the MALT1 tumor suppressor is an antisense oligonucleotide, and its nucleotide sequence is shown in any one of SEQ ID Nos. 2-6 and 8-12.

[0150] As certain embodiments of the present invention, the nucleotide sequence of the antisense oligonucleotide is shown in any one of SEQ ID No. 2-3.

[0151] As certain embodiments of the present invention, the antisense oligonucleotide is chemically modified.

[0152] As certain embodiments of the present invention, the antisense oligonucleotide further comprises a modified internucleoside linkage.

[0153] As certain embodiments of the present invention, the antisense oligonucleotide further comprises a modified sugar.

[0154] As certain embodiments of the present invention, the antisense oligonucleotide further comprises a modified nucleobase.

[0155] As certain embodiments of the present invention, the antisense oligonucleotide is delivered by a drug delivery system.

[0156] In certain embodiments of the present invention, the pharmaceutical composition alters the microenvironment of tumor cells, causing macrophages to transform from M2 to M1. The pharmaceutical composition alters the microenvironment of tumor tissue, significantly reducing the number of macrophages in the tumor tissue and transforming the macrophages in the tumor tissue from M2 to M1.

[0157] As certain embodiments of the present invention, the pharmaceutical composition further comprises a second drug.

[0158] As certain embodiments of the present invention, the second drug is selected from an immune checkpoint inhibitor, a chemotherapeutic agent, or a MALT1 enzyme activity inhibitor.

[0159] As certain embodiments of the present invention, the MALT1 enzyme activity inhibitor is a small molecule inhibitor.

[0160] As certain embodiments of the present invention, the immune checkpoint inhibitor is selected from PD-L1, PD-L2, PD-1, CTLA-4, TIM-3, LAG-3, VISTA or TIGIT inhibitors.

[0161] As certain embodiments of the present invention, the PD-1 inhibitor is selected from nivolumab, pembrolizumab, avelumab, cemiplimab, BGB-A317, sintilimab, toripalimab, camrelizumab, or tislelizumab.

[0162] As certain embodiments of the present invention, the PD-L1 inhibitor is selected from atezolizumab or durvalumab.

[0163] As certain embodiments of the present invention, the CTLA-4 inhibitor is selected from ipilimumab or tremelimumab.

[0164] As certain embodiments of the present invention, the chemotherapeutic agent is selected from alkylating agents, antimetabolites, antitumor antibiotics, plants, hormones, and other types of chemotherapeutic agents.

[0165] In certain embodiments of the present invention, the alkylating agent is selected from nimustine, carmustine, lomustine, cyclophosphamide, ifosfamide, or glyphosate mustard.

[0166] In certain embodiments of the present invention, the antimetabolite is selected from doxiflurane, doceflurane, 5-fluorouracil, mercaptopurine, thioguanine, fluguanidine, fumaridine, gemcitabine, fluorouracil, hydroxyurea, methotrexate, eufotaxime, or ancitabine.

[0167] As certain embodiments of the present invention, the antitumor antibiotic is selected from actinomycin D, doxorubicin, daunorubicin, epirubicin, mitomycin, bleomycin, or pirarubicin.

[0168] As certain embodiments of the present invention, the anti-tumor plant or animal component drug is selected from irinotecan, harringtonine, hydroxycamptothecin, vinorelbine, paclitaxel, taxotere, topotecan, vincristine, vindesine, vinblastine, vinblastine, teniposide, etoposide, or elemene.

[0169] As certain embodiments of the present invention, the anti-tumor hormones are selected from atamestane, anastrozole, aminoglutethimide, letrozole, formestane, medroxyprogesterone acetate, tamoxifen, or breast cancer inhibitors.

[0170] In certain embodiments of the present invention, the other class of chemotherapeutic agents is selected from asparaginase, carboplatin, cisplatin, dacarbazine, oxaliplatin, eloxatin, oxaliplatin, mitoxantrone, or procarbazine.

[0171] As certain embodiments of the present invention, the small molecule inhibitor.

[0172] As certain embodiments of the present invention, the small molecule inhibitor is selected from compounds having any one of the following structural formulas 1 to 47:

[0173]

[0174] Wherein, R is H; Wherein, R is methyl;

[0175] Wherein, R is H; Wherein, R is Br;

[0176] Wherein, R is H; Wherein, R is OH;

[0177]

[0178] wherein R is a methyl group; Where R is H;

[0179]

[0180] The present invention also provides a pharmaceutical combination product comprising an effective amount of the MALT1 tumor inhibitor according to any one of claims 1 to 13 and a second drug for simultaneous or sequential administration.

[0181] As certain embodiments of the present invention, the MALT1 tumor suppressor is an antisense oligonucleotide, and its nucleotide sequence is shown in any one of SEQ ID Nos. 2-6 and 8-12.

[0182] As certain embodiments of the present invention, the nucleotide sequence of the antisense oligonucleotide is shown in any one of SEQ ID No. 2-3.

[0183] As certain embodiments of the present invention, the antisense oligonucleotide is chemically modified.

[0184] As certain embodiments of the present invention, the antisense oligonucleotide further comprises a modified internucleoside linkage.

[0185] As certain embodiments of the present invention, the antisense oligonucleotide further comprises a modified sugar.

[0186] As certain embodiments of the present invention, the antisense oligonucleotide further comprises a modified nucleobase.

[0187] As certain embodiments of the present invention, the antisense oligonucleotide is delivered by a drug delivery system.

[0188] As certain embodiments of the present invention, the drug combination product changes the microenvironment of tumor tissue, significantly reduces the number of macrophages in tumor tissue, and converts the macrophages in tumor tissue from M2 to M1.

[0189] As certain embodiments of the present invention, the second drug is selected from an immune checkpoint inhibitor or a chemotherapeutic agent.

[0190] As certain embodiments of the present invention, the immune checkpoint inhibitor is selected from PD-L1, PD-L2, PD-1, CTLA-4, TIM-3, LAG-3, VISTA or TIGIT inhibitors.

[0191] As certain embodiments of the present invention, the PD-1 inhibitor is selected from nivolumab, pembrolizumab, avelumab, cemiplimab, BGB-A317, sintilimab, toripalimab, camrelizumab, or tislelizumab.

[0192] As certain embodiments of the present invention, the PD-L1 inhibitor is selected from atezolizumab or durvalumab.

[0193] In certain embodiments of the present invention, the CTLA-4 inhibitor is selected from ipilimumab or tremelimumab.

[0194] As certain embodiments of the present invention, the chemotherapeutic agent is selected from alkylating agents, antimetabolites, antitumor antibiotics, plants, hormones, and other types of chemotherapeutic agents.

[0195] In certain embodiments of the present invention, the alkylating agent is selected from nimustine, carmustine, lomustine, cyclophosphamide, ifosfamide, or glyphosate mustard.

[0196] In certain embodiments of the present invention, the antimetabolite is selected from doxiflurane, doceflurane, 5-fluorouracil, mercaptopurine, thioguanine, fluguanidine, fumaridine, gemcitabine, fluorouracil, hydroxyurea, methotrexate, eufotaxime, or ancitabine.

[0197] As certain embodiments of the present invention, the antitumor antibiotic is selected from actinomycin D, doxorubicin, daunorubicin, epirubicin, mitomycin, bleomycin, or pirarubicin.

[0198] As certain embodiments of the present invention, the anti-tumor plant or animal component drug is selected from irinotecan, harringtonine, hydroxycamptothecin, vinorelbine, paclitaxel, taxotere, topotecan, vincristine, vindesine, vinblastine, vinblastine, teniposide, etoposide, or elemene.

[0199] As certain embodiments of the present invention, the anti-tumor hormones are selected from atamestane, anastrozole, aminoglutethimide, letrozole, formestane, medroxyprogesterone acetate, tamoxifen, or breast cancer inhibitors.

[0200] In certain embodiments of the present invention, the other class of chemotherapeutic agents is selected from asparaginase, carboplatin, cisplatin, dacarbazine, oxaliplatin, eloxatin, oxaliplatin, mitoxantrone, or procarbazine.

[0201] The present invention also provides the use of the MALT1 tumor inhibitor, the pharmaceutical composition, or the pharmaceutical combination product in the treatment of diseases, wherein the diseases include tumors.

[0202] As certain embodiments of the present invention, applicable diseases are solid tumors; the solid tumors include but are not limited to malignant tumors occurring in the lungs, pancreas, liver, digestive tract, reproductive system, etc., such as Hodgkin's lymphoma, non-Hodgkin's lymphoma, lung cancer, breast cancer (including triple-negative breast cancer), melanoma, ovarian cancer, gastric cancer, colon cancer, rectal cancer, liver cancer, pancreatic cancer, head and neck malignancies, urinary system malignancies, endometrial cancer, cervical cancer, osteosarcoma, chondrosarcoma, Ewing's sarcoma, thyroid cancer, hepatoblastoma, and Wilms' tumor.

[0203] As certain embodiments of the present invention, the administration route is topical administration or intravenous administration.

[0204] In certain embodiments of the present invention, the pharmaceutical composition of the present invention is administered by a route selected from intravenous injection, intramuscular injection, subcutaneous injection, rectal instillation (rectal administration), eye drops, nasal spray, or oral spray (inhalation), and can also be administered topically (topically) or systemically (transdermally). The preferred route of administration is intravenous injection or subcutaneous injection.

[0205] As certain embodiments of the present invention, indications include solid tumors; the solid tumors include but are not limited to malignant tumors occurring in the lungs, pancreas, liver, digestive tract, reproductive system, etc., such as Hodgkin's lymphoma, non-Hodgkin's lymphoma, lung cancer, breast cancer (including triple-negative breast cancer), melanoma, ovarian cancer, gastric cancer, colon cancer, rectal cancer, liver cancer, pancreatic cancer, head and neck malignancies, urinary system malignancies, endometrial cancer, cervical cancer, osteosarcoma, chondrosarcoma, Ewing's sarcoma, thyroid cancer, hepatoblastoma, and Wilms' tumor.

[0206] In certain embodiments of the present invention, the applicable subject is a mammal.

[0207] In certain embodiments of the present invention, the applicable subject is human.

[0208] The present invention also includes a commercial kit, which includes the pharmaceutical composition or drug combination and instructions for use of the pharmaceutical composition or drug combination, wherein the instructions describe the administration method and dosage of the pharmaceutical composition.

[0209] The present invention provides a method for treating a disease, which targets the MALT1 death domain, the gene expressing it, or the protein-protein interaction site between MALT1 and BCL-10; the method comprises inhibiting, knocking out, changing the structure, or degrading the MALT1 death domain, thereby reducing or losing the ability of MALT1 and BCL-10 to form a complex.

[0210] As certain embodiments of the present invention, the MALT1 tumor inhibitor, the pharmaceutical composition, or the pharmaceutical combination product is used as a therapeutic drug.

[0211] As certain embodiments of the present invention, the treatment method changes the microenvironment of tumor tissue, significantly reduces the number of macrophages in tumor tissue, and converts macrophages from M2 to M1.

[0212] As certain embodiments of the present invention, the treatment method further comprises a combination with a tumor treatment method selected from surgery, radiotherapy, chemotherapy, or immunotherapy.

[0213] As certain embodiments of the present invention, the immunotherapy is selected from nonspecific immune stimulation, oncolytic virus therapy, adoptive cell and gene-modified immune cells, tumor vaccines, immune checkpoint monoclonal antibodies (PD1 / CLAT4) and T cell-based immunotherapy.

[0214] As certain embodiments of the present invention, nonspecific immune stimulation includes interferon and interleukin. Interferon enhances the immune system to carry out programmed cell death and / or slow down the growth of cancer cells with targeted cancer cells. Interleukins (such as interleukin 2, IL-2 or aldesleukin (Proleukin)) enhance the immune system to produce cells that target cancer cells and carry out programmed cell death. Interleukins are used to treat, for example, renal cancer and skin cancer, including melanoma. Nonspecific immunotherapy can be given as a monotherapy, or can be given after or simultaneously with another anticancer therapy (such as chemotherapy or radiotherapy).

[0215] As certain embodiments of the present invention, the oncolytic virus therapy utilizes genetically modified viruses (such as herpes simplex virus or other viruses) to target cancer cells to induce programmed cell death through an immune response.

[0216] As certain embodiments of the present invention, the T cell-based immunotherapy is selected from CAR-T therapy, TCR-T therapy, TILs therapy, or CTL therapy.

[0217] As certain embodiments of the present invention, a patient is administered a combination of the pharmaceutical composition described herein and CAR-T cells targeting the following substances: EGFR (epidermal growth factor receptor) on non-small cell lung cancer, epithelial cancer, and glioma; EGFRvIII (variant III of epidermal growth factor receptor) on glioblastoma; HER2 (human epidermal growth factor receptor 2) on ovarian cancer, breast cancer, glioblastoma, colon cancer, osteosarcoma, and medulloblastoma; MSLN (mesothelin) on mesothelioma, ovarian cancer, and pancreatic adenocarcinoma; PSMA (prostate-specific membrane antigen) on prostate cancer; CEA (carcinoembryonic antigen) on pancreatic adenocarcinoma, breast cancer, and colorectal epithelial cancer; GD2 (disialoganglioside 2) on neuroblastoma and melanoma; IL13Rα2 (interleukin-13) on glioma. The following proteins are expressed in the blood: Ra2); GPC3 (Glypican-3) on hepatocellular carcinoma; CAIX (Carbonic Anhydrase IX) on renal cell carcinoma (RCC); L1-CAM (L1 cell adhesion molecule) on neuroblastoma, melanoma, and ovarian adenocarcinoma; CA125 (Cancer Antigen 125, also known as MUC16) on epithelial ovarian cancer; CD133 (Cluster of Differentiation 133, also known as prominin-1) on glioblastoma and cholangiocarcinoma (CCA); FAP (Fibroblast Activation Protein) on malignant pleural mesothelioma (MPM); CTAG1B (Cancer / Testis Antigen 1B, also known as NY-ESO-1) on melanoma and ovarian cancer; MUC1 (Mucin 1) on seminal vesicle cancer; FR-α (Folic Acid Receptor-α) on ovarian cancer.

[0218] As certain embodiments of the present invention, the disease comprises a tumor, further a solid tumor.

[0219] As certain embodiments of the present invention, the solid tumors include but are not limited to malignant tumors occurring in the lungs, pancreas, liver, digestive tract, reproductive system, etc., such as Hodgkin's lymphoma, non-Hodgkin's lymphoma, lung cancer, breast cancer (including triple-negative breast cancer), melanoma, ovarian cancer, gastric cancer, colon cancer, rectal cancer, liver cancer, pancreatic cancer, head and neck malignancies, urinary system malignancies, endometrial cancer, cervical cancer, osteosarcoma, chondrosarcoma, Ewing's sarcoma, thyroid cancer, hepatoblastoma, and Wilms' tumor.

[0220] As certain embodiments of the present invention, the subject of the treatment method is a mammal.

[0221] In certain embodiments of the present invention, the subject of the treatment method is a human.

[0222] The present invention also provides a target, which is an interaction site between MALT1 and BCL-10 proteins, or a nucleotide sequence encoding the same.

[0223] In some embodiments of the present invention, the target is amino acid residues 64 to 114 based on the MALT1 amino acid sequence shown in SEQ ID No. 1, or a nucleotide sequence encoding the same.

[0224] In some embodiments of the present invention, the target is the 81st and / or 82nd amino acid residue based on the MALT1 amino acid sequence shown in SEQ ID No. 1, or the corresponding codons in the nucleotide sequence encoding the same.

[0225] The present invention also provides the use of the target in screening drugs, wherein a drug for treating tumors acts on the target, and the drug includes an inhibitor of the protein binding between MALT1 and BCL-10.

[0226] The present invention also provides an inhibitor, which acts on the target and inhibits the interaction between MALT-1 and BCL10.

[0227] In order to make the technical means, creative features, objectives and effects achieved by the present invention easier to understand, the technical solutions in the embodiments of the present invention will be clearly and completely described below in conjunction with the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making creative efforts shall fall within the scope of protection of the present invention.

[0228] In the examples of the present invention, mouse MALT1-1 protein and its mRNA, and human MALT1-1 protein and its mRNA are used as examples to illustrate the function of the tumor effector region on the MALT1-1 death domain and the role of MALT1 as a tumor suppressor.

[0229] Example 1

[0230] This example uses an in situ mammary fat pad injection model to determine the effects of different mutation sites in the MALT1 death domain gene mutant on tumor growth. The amino acid sequence of the mouse MALT1 protein is shown in SEQ ID No. 22 (NCBI Reference Sequence: NP_766421.1).

[0231] The experimental results are shown in Figure 5. As shown in Figure 5, overexpression of MALT1 para-caspase active center gene mutations promoted tumor cell growth. However, under the premise of MALT1 para-caspase active center mutations, such as mutations at valine 87 and / or leucine 88 in the MALT1 death domain (corresponding to lanes D and E in Figure 5, respectively), overexpression of these MALT1 para-caspase active center gene mutations lost their tumor growth-promoting effect.

[0232] This experiment shows that the amino acid residues at positions 87 and / or 88 of the MALT1 death domain play a key role in promoting tumor growth by other MALT1 mutations, which correspond to the amino acid residues 81 and / or 82 of the human MALT-1 death domain amino acid sequence (for example, the human MALT-1 death domain amino acid sequence shown in SEQ ID No.1 (NCBI Reference Sequence: NP_006776.1)).

[0233] Example 2

[0234] In this experiment, immunoprecipitation (IP) was used to study and analyze the interaction sites between MALT1 and BCL10.

[0235] Co-immunoprecipitation is a method used to study protein interactions. This method can be used to selectively enrich specific protein complexes and study the protein members and their interactions.

[0236] Specifically, for MALT1 and BCL10, monoclonal antibodies need to be prepared to specifically recognize the two proteins respectively. These two antibodies are then bound to the corresponding antigenic proteins (i.e., MALT1 and BCL10) to form MALT1-antibody and BCL10-antibody complexes. These complexes are then incubated with cell lysate to allow the complexes to bind non-specifically to other components. Proteins that are not specifically bound to the complexes can be washed away by subsequent centrifugation and washing. Finally, the resulting co-precipitated complex can be used for Western blot analysis to determine whether MALT1 and BCL10 interact and bind. If MALT1 and BCL10 bind, the complex should be effectively enriched, and the results of the Western blot test should show a high correlation. Conversely, if the complex cannot be sufficiently enriched or the test result is negative, it can be indicated that there is no interaction between the two.

[0237] The specific operations are as follows:

[0238] 2.1 Cell Preparation

[0239] S1. E0771-TR was infected with the lentivirus pLKO.1-puro MALT1 shRNA1 and selected with puromycin to generate E0771-TR MALT1-KD cells. S2. E0771-TR was infected with the retrovirus MSCV-Puro-MALT1-wild-type and selected with puromycin to generate E0771-TR MALT1-wild-type overexpressing cells. S3. E0771-TR was infected with the retrovirus MSCV-Puro-MALT1-C83A and selected with puromycin to generate E0771-TR MALT1-C83A overexpressing cells. S4. E0771-TR was infected with the retrovirus MSCV-Puro-MALT1-V87R and selected with puromycin to generate E0771-TR MALT1-V87R overexpressing cells. S5. E0771-TR was infected with the retrovirus MSCV-Puro-MALT1-L88D, and puromycin selection was used to obtain E0771-TR MALT1-L88D-overexpressing cells. S6. E0771-TR was infected with the retrovirus MSCV-Puro-MALT1-E104R, and puromycin selection was used to obtain E0771-TR MALT1-E104R-overexpressing cells. S7. E0771-TR was infected with the retrovirus MSCV-Puro-MALT1-C461A, and puromycin selection was used to obtain E0771-TR MALT1-C461A-overexpressing cells. S8. E0771-TR was infected with the retrovirus MSCV-Puro-MALT1-C83R-C461A, and puromycin selection was used to obtain E0771-TR MALT1-C83A-C461A overexpressing cells. S9. E0771-TR was infected with the retrovirus MSCV-Puro-MALT1-V87R-C461A, and puromycin selection was used to obtain E0771-TR MALT1-V87R-C461A overexpressing cells. S10. E0771-TR was infected with the retrovirus MSCV-Puro-MALT1-L88D-C461A, and puromycin selection was used to obtain E0771-TR MALT1-L88D-C461A overexpressing cells. S11. E0771-TR was infected with the retrovirus MSCV-Puro-MALT1-E104R-C461A, and E0771-TR MALT1-E104R-C461A overexpressing cells were obtained after Puromycin selection.

[0240] 2.2 The 11 cell lines obtained in 2.1 were infected with the lentivirus pLVX-BCL10-3XFlag-Blast. After blasticidin selection, the following 11 cell lines were obtained:

[0241] 1. Overexpression cell line of BCL10 containing three repeat FLAG in E0771-TR MALT1-KD cells (negative control); 2. Overexpression cell line of BCL10 containing three repeat FLAG in E0771-TR MALT1-wild group overexpression cells (positive control); 3. Overexpression cell line of BCL10 containing three repeat FLAG in E0771-TR MALT1-C83A overexpression cells; 4. Overexpression cell line of BCL10 containing three repeat FLAG in E0771-TR MALT1-V87R overexpression cells; 5. Overexpression cell line of BCL10 containing three repeat FLAG in E0771-TR MALT1-L88D overexpression cells; 6. Overexpression cell line of BCL10 containing three repeat FLAG in E0771-TR 7. Overexpression cell line in MALT1-E104R overexpressing cells; 8. Overexpression cell line in E0771-TR MALT1-C83A-C461A overexpressing cells containing three repeat FLAGs; 9. Overexpression cell line in E0771-TR MALT1-V87R-C461A overexpressing cells containing three repeat FLAGs; 10. Overexpression cell line in E0771-TR MALT1-L88D-C461A overexpressing cells containing three repeat FLAGs; 11. Overexpression cell line in E0771-TR MALT1-E104R-C461A overexpressing cells containing three repeat FLAGs

[0242] 2.3 The 11 cell lines obtained in 2.2 were plated into 6-well plates with 5*105 cells per well. After 24 hours, the cells were lysed with cell lysis buffer.

[0243] The formula of cell lysis buffer is as follows:

[0244] 10 mM Tris, pH 7.4; 100 mM NaCl; 1 mM EDTA; 1 mM EGTA; 1 mM NaF; 20 mM Na₄P₂Oₐ; 2 mM Na₃VO₄; 1% Triton X-100; 10% glycerol; 0.1% SDS; 0.5% deoxycholate

[0245] 2.4 The specific process of co-immunoprecipitation is as follows:

[0246] 2.4.1 Preparation of microbeads

[0247] 1. Prepare 3 μL of concentrated beads for each cell lysate sample from 6-well plate 2.

[0248] 2. Transfer the beads to each 1.5 mL microcentrifuge tube and wash the beads 3 times with cell lysis buffer

[0249] (1) Resuspend the beads in 200 μL cell lysis buffer

[0250] (2) Centrifuge at 14,000 g for 30 s and remove the supernatant with the help of a magnetic stand.

[0251] 2.4.2 Immunoprecipitation and incubation

[0252] 1. Lyse 200 μL of cells per sample and add 160 μL of cell lysate to each tube, with 160 μL for IP and 40 μL for input.

[0253] 2. (Optional) Add 640 μL of cell lysis buffer (with protease inhibitor cocktail) to each tube to allow for more thorough mixing.

[0254] 3. Invert the tube at 4°C overnight

[0255] 2.4.3 Cleaning and elution

[0256] 1. Centrifuge the tube at 14,000 g for 30 s and remove the supernatant with the help of a magnetic stand 7.

[0257] 2. Wash the beads 5 times with 500 μL cell lysis buffer (containing protease inhibitor cocktail) per tube

[0258] (1) Add 500 μL of cell lysis buffer to each tube; (2) Rotate the tube upside down at 4°C for 10 minutes; (3) Centrifuge at 14,000 g for 30 seconds and remove the supernatant with the help of a magnetic stand 8.

[0259] 3. Resuspend the beads in 60-100 μL SDS loading buffer 9.

[0260] 4. Heat the mixture at 95°C for 5 minutes. 10. Centrifuge at 14,000 g for 1 minute.

[0261] 5. The supernatant is used as the sample for SDS-PAGE.

[0262] 2.4.4 Perform SDS-PAGE electrophoresis on the 11 samples in 2.4.3

[0263] Samples numbered 1-11 represent lysed samples from the 11 cell lines described in 2.2. The results in Figure 7 demonstrate that the V87R and L88D mutations in the MALT1 death domain affect the binding of MALT1 to BCL10 (the intensity of the red boxes in Figure 7 is essentially the same as that of the blue boxes under MALT1 knockdown). Furthermore, cell lines 7-11 exhibit the same trend as cell lines 2-6, demonstrating that the binding of MALT1 to BCL10 is unrelated to the MALT1 para-caspase mutation (C461A).

[0264] This experiment shows that amino acids 87 and / or 88 in the MALT1 death domain play a key role in the binding of MALT1 to BCL10.

[0265] Example 3

[0266] This example provides a method for co-culturing tumor cells, macrophages, and somatic cells, demonstrating that mutations in V87R and L88D weaken the effects of the death domain on macrophages.

[0267] 3.1 Acquisition and culture of macrophages

[0268] 1. Sacrifice 10-12 week old mice (sex should be recorded). Isolate the bones from both hands and feet and soak them in PBS. 2. Cut the bones at both ends. Using a 1 mL syringe with a 1 mL needle, flush the bone marrow with regular DMEM into a 50 mL tube fitted with a 70 μm sterile cell strainer (approximately 20 mL of culture medium is used for 6 small bones per mouse). 3. Centrifuge at 300 g for 3 minutes. 4. Discard the supernatant, add 2 mL of 1× lysis buffer and incubate at room temperature for 1 minute. Immediately add 5 mL of regular DMEM to terminate the incubation. 5. Centrifuge at 300 g for 3 minutes. 6. Discard the supernatant and wash once with 2 mL of PBS. 7. Centrifuge at 300 g for 3 minutes. 8. Discard the supernatant and resuspend the cells in 2 mL of BMDM medium (DMEM + 20% BI FBS + 10 ng / mL M-CSF + HEPES (100×) + GLUTMAX (100×)). Pass the cells through a 70 μm sterile cell strainer. 9. Count the cells and adjust the cell concentration to 2×106 cells / mL using BMDM medium. Add 10 mL to a 10 cm dish. 10. Incubate at 37°C for 48 hours. 11. After 48 hours, perform the first medium change. Aspirate 8 mL of medium, leaving approximately 2 mL. Add 10 mL of BMDM medium (DMEM + 20% BI FBS + 10 ng / mL M-CSF + HEPES (100×) + GLUTMAX (100×)). Continue incubating at 37°C for 24 hours. 12. After 24 hours, perform the second medium change. Aspirate all the medium, wash once with PBS, and add 10 mL of BMDM medium (DMEM + 20% BI FBS + 20 ng / mL M-CSF + HEPES (100×) + GLUTMAX (100×)). Continue incubating at 37°C for 24 hours. 13. After 24 hours, when the macrophages have grown for 96 hours, remove the culture dish, wash twice with PBS, and digest with 3 mL of trypsin at room temperature for 3 minutes. Aspirate the trypsin to remove monocytes. 14. Add 3 mL of trypsin and digest at 37°C for 12 minutes. Terminate without adding culture medium. Split the cells directly with trypsin and add them to a 15 mL tube containing 5 mL of DMEM. Centrifuge at 300 g for 3 minutes. 15. Discard the supernatant, resuspend in 1 mL of PBS, and centrifuge at 300 g for 3 minutes. 16. Discard the supernatant, resuspend in 1 mL of DMEM, count, and adjust to the desired concentration.

[0269] 3.2 T cell acquisition and culture

[0270] 1. Coat one well of a 6-well plate with anti-CD3 and anti-CD28 8-12 hours in advance. Add 1 mL PBS, 1 μL anti-CD3, and 2 μL anti-CD28, mix well, and refrigerate at 4°C. 2. Sacrifice 6-8 week-old OT-1 mice (same sex as wild-type mice in the same experiment), isolate the spleen and mammary lymph nodes, and soak in PBS. 3. In a laminar flow hood, transfer the spleen and lymph nodes to a 1.5 mL EP tube containing 200 μL 1640 regular medium. 4. Mince the spleen and lymph nodes and filter the cell suspension through a 50 mL tube fitted with a 70 μm sterile cell strainer. 5. Centrifuge at 300 g for 3 minutes. 6. Discard the supernatant and add 2 mL of 1× lysis buffer and incubate at room temperature for 1 minute. Immediately add 5 mL of 1640 regular medium to terminate the reaction. 7. Centrifuge at 300 g for 3 minutes. 8. Discard the supernatant and add 2 mL of PBS to wash once. 9. Centrifuge at 300 g for 3 minutes. 10. Discard the supernatant and resuspend in 2 mL of PBS. Pass the cell through a 70 μm sterile cell sieve. 11. Count the cells and adjust the cell density to 1 × 10 using 1 × MoJoSort buffer. 8 cells / mL. 12. Remove 200 μL of cell suspension for CD8 T cell isolation. 13. Wash the isolated cells once with PBS and resuspend in 2 mL of TCM (1640 + 20% BI FBS + 20 ng / mL IL2 + HEPES (100×) + GLUTMAX (100×) + sodium pyruvate (100×) + beta-mercaptoethanol (1000×)). 14. Remove the coated plate, aspirate the liquid, wash once with 1 mL of PBS, add the cell suspension, and incubate at 37°C for 48 hours. 15. After 48 hours, transfer the T cells from the 6-well plate to a 10 cm dish and incubate at 37°C for 24 hours. 16. After 24 hours, transfer the T cells from the 10 cm dish to the 10 cm dish at a ratio of 1:3 and incubate at 37°C for 24 hours. 17. After 24 hours, the T cells are 96 hours old and in peak condition and can be used. 18. Before adding T cells, incubate with 100 ng / mL OVA for 2 hours. 19. Aspirate the medium containing OVA and add DMEM medium containing the specified number of T cells or medium without T cells.

[0271] 3.3 Preparation of tumor cell culture medium

[0272] 1. Count the cells and plate the cells with DMEM. 2. 48 hours after adding macrophages, perform the first culture medium change with DMEM.

[0273] 3. 2 hours before adding T cells, incubate with 100 ng / mL OVA, then aspirate the OVA and add fresh medium with or without T cells. 4. 24 hours later, aspirate the medium and add 500 μL of 1× lysis buffer to the 6-well plate or 200 μL of 1× lysis buffer to the 24-well plate.

[0274] 3.4 Determination of tumor cell survival using luciferase assay

[0275] The results are shown in FIG8 , which shows the survival rates of tumor cells in 11 cell lines before and after the addition of macrophages.

[0276] The experimental results showed that there was no difference in tumor cell survival rate between cell lines 1-6, indicating that the presence of corresponding MALT1 mutants cannot enhance tumor cell survival when only T cells are present.

[0277] Macrophages themselves enhance tumor cell survival (7 vs. 1). Once macrophages are added, a comparison of the tumor cell survival rates of cell lines 7-12 (with macrophages added) versus those of cell lines 8, 9, and 12 on the right demonstrates that MALT1 further enhances macrophage protection against tumors (tumor cell survival rate ratio of cell lines 8, 9, and 12 versus cell line 7). However, when amino acids 87 and / or 88 in the MALT1 death domain are mutated, the protective effect of MALT1 is lost, and the tumor cell survival rates of cell lines 7, 10, and 11 become essentially the same.

[0278] This experiment shows that MALT1 protects tumor cells by enhancing the protection of macrophages against tumors; and this protective effect depends on the structure formed by amino acids at positions 87 and / or 88 of the death domain.

[0279] Example 4

[0280] This example studies the effect of cell-conditioned medium on macrophage proliferation.

[0281] 4.1 Cell-conditioned medium

[0282] 2×10 6 The cells were plated onto 10 cm of DMEM conventional culture medium (DMEM+10% FBS+1% PS). After 36 hours, the culture medium was collected and centrifuged at 3500 g for 10 minutes. The supernatant was filtered using a 0.45 μm filter membrane to obtain the conditioned culture medium.

[0283] 4.2 Methods for culturing macrophages using cell-conditioned medium

[0284] Add 1 ml of 1×10 6 cells / mL macrophage suspension (in this case, macrophage culture medium DMEM+10% FBS+1% PS+1% Glut MAX+10ng / ml M-SCF) was used, and then 1 ml of conditioned medium was added to each well, mixed, and cultured for 48 h for counting.

[0285] 4.3 Cell number determination method

[0286] Macrophages were digested with trypsin at 37°C for 15 minutes, centrifuged at 300 g for 3 minutes, the supernatant was discarded, the cells were diluted to an appropriate multiple, stained with trypan blue, and counted on a hemocytometer.

[0287] The results are shown in FIG9 and FIG10 , wherein FIG10 is a visualization result of the cell number obtained by directly photographing under a microscope.

[0288] Cell lines 3-6 were mutated under the MALT1 wild-type group, and cell lines 8-11 were mutated under the condition of MALT1 para-caspase active center mutation. Comparison of cell lines 2 and 7 with cell line 1 shows that the effect of MALT1 on macrophage proliferation is independent of para-caspase activity. However, once V87R (cell lines 4 and 9) and L88D (cell lines 5 and 10) mutations are introduced, the effect of MALT1 on macrophage proliferation disappears immediately (comparison of cell lines 4 and 5 with cell line 2) and (comparison of cell lines 9 and 10 with cell line 7).

[0289] This experiment shows that amino acids at positions 87 and / or 88 in the MALT1 death domain weaken the effect of the MALT1 death domain on macrophages.

[0290] Example 5

[0291] This example studies the effect of mutations in the MALT1 death domain gene on the killing ability of T cells.

[0292] The experimental results are shown in Figure 11, which shows a single-parameter histogram of flow cytometry results. Column 1 represents the control group, column 2 represents the MALT1 wild-type group, and columns 3-6 represent the MALT1 wild-type group with mutations. As can be seen, columns 3-6 show no significant differences from column 2, indicating that mutations in the MALT1 death domain gene have no effect on T cell cytotoxicity alone.

[0293] The results showed that amino acid mutations at positions 87 and / or 88 in the MALT1 death domain did not affect the protection of MALT1 Para-caspase against tumor cells in the presence of T cells alone.

[0294] This experiment shows that the structure formed by amino acids 87 and / or 88 in the MALT1 death domain has nothing to do with the effect of MALT1 Para-caspase on T cells.

[0295] Example 6

[0296] In this example, flow cytometry was used to detect the infiltration of tumor immune cells in mice.

[0297] The experimental results are shown in Figures 11 and 12.

[0298] Figure 11 shows the results of flow cytometry. Figure 1 represents the control cell line, 2 represents a cell line with a mutation in the MALT1 para-caspase active center, and 3-6 represent cell lines with additional mutations based on Figure 2. These cell lines were injected into the mammary fat pad of mice, and tumors were harvested on day 15 for flow cytometric analysis. The upper right corner of the first row of images shows intratumoral macrophages. As can be seen, macrophage infiltration increased in cells 2, 3, and 6 compared to cell 1, but mutations 4 (V87R) and 5 (L88D) reduced intratumoral macrophage levels to levels similar to those in cell 1.

[0299] In Figure 12, the left figure shows the ratio of mutants at different sites of the MALT1 death structure to macrophages, the middle figure shows the correspondence between mutants at different sites of the MALT1 death structure and CD206 intensity (M2 marker), and the right figure shows the correspondence between mutants at different sites of the MALT1 death structure and MHCI intensity (M1 marker). Simply put, M2 promotes tumors and M1 inhibits tumors. We can see that mutations in 4 (V87R) and 5 (L88D) reduce M2 and increase M1 in macrophages within the tumor, while mutations in 2, 3, and 6 show a high M2 ratio and a low M1 ratio.

[0300] Figure 13 shows the T cell infiltration of each mouse tumor as assessed by flow cytometry. Column 1 in the figure below represents the control group, column 2 represents the group with a MALT1 para-caspase active site mutation, and columns 3-6 represent the group with additional mutations based on column 2. These cells were injected into the mammary fat pad of mice, and tumors were harvested for flow cytometric analysis on day 15. The upper left corner of the first row of images shows CD4 T cells, while the lower right corner shows CD8 T cells. Columns 2, 3, and 6 show a decrease in CD8 T cell infiltration relative to column 1. However, mutations 4 (V87R) and 5 (L88D) restore tumor CD8 T cell infiltration to levels similar to those in column 1. However, these mutations have little effect on CD4 T cell infiltration.

[0301] The results showed that the V87R and L88D mutations in the MALT1 death domain weakened the effect of the MALT1 death domain on macrophages, thereby weakening the effect of MALT1 on reducing the infiltration of CD8 T cells, and this was still true in the presence of tumors in vivo.

[0302] This experiment shows that the structure formed by amino acids at positions 87 and / or 88 of the MALT1 death domain can protect tumor cells in animals, and this effect is based on its effect on macrophages.

[0303] Based on the aforementioned examples, we can conclude that a structure within the MALT1 protein protects tumor cell growth, stemming from its effect on macrophages in the tumor environment. Amino acids 87 and / or 88 within the MALT1 protein's death domain play a key role in this structure, and these amino acids are also key sites for MALT1 binding to BCL10.

[0304] Based on the aforementioned examples, the following conclusions can be drawn: Mutating amino acids at positions 87 and / or 88 of the MALT1 protein can disrupt its structure, thereby destroying the protective effect of the MALT1 protein on tumor cell growth, thereby inhibiting tumor growth. Disrupting the binding of MALT1 to BCL10 can also disrupt the protective effect of the MALT1 protein on tumor cell growth, thereby inhibiting tumor growth.

[0305] It should be noted that, in the present application, there is no specific limitation on the drug type and form of MALT1 tumor inhibitor, including but not limited to those listed above, and the specific selection can be made according to actual conditions.

[0306] In the present application, MALT1 tumor inhibitors that inhibit the activity of the MALT1 tumor effector domain can be used to treat all cancers and should not be limited to the cancer types listed in this application document.

[0307] Example 7

[0308] The preparation of antisense oligonucleotides for inhibiting MALT1, using an antisense nucleic acid strategy, includes the following steps:

[0309] S1. Considering the specificity between the antisense nucleic acid and the target nucleic acid and the hairpin-like structure that may be formed by base complementarity within the nucleotide sequence of the antisense nucleic acid, the nucleotide sequence of the antisense nucleic acid needs to target the 81st and / or 82nd amino acid residues of the death domain DD of MALT1; S2. Considering the stability of hybridization and the permeability of the antisense oligonucleotide to the cell membrane, the length of the antisense oligonucleotide is selected, and the range of the antisense oligonucleotide is 15 to 40 bases; S3. Considering the affinity of the antisense oligonucleotide to the target sequence, since the affinity of GC base pairs is greater than the affinity between AU, increasing the ratio of GC base pairs to AU base pairs in the antisense oligonucleotide can appropriately reduce the length of the antisense oligonucleotide; S4. Setting a control, and using missense or reverse as a control; S5. Using the designed antisense oligonucleotide to inhibit the expression of MALT-1 mRNA with the same target sequence, and screening the antisense oligonucleotide with the best inhibitory effect.

[0310] The specific steps for screening the antisense oligonucleotide with the best inhibitory effect are as follows:

[0311] a, 2×10 5 E0771 cells were transfected into each well of a 12-well plate and placed overnight;

[0312] b, The day after operation a was completed, 5 μL Lipofectamine TM 3000 cells were transfected with the corresponding ASO drugs until the final concentration reached 50 nM.

[0313] c, 6 hours after the completion of the operation in b, the serum-free medium was replaced with a medium containing 10% serum.

[0314] d, c 24 hours after the completion of the operation, the serum-free medium was replaced again;

[0315] e, 48 h after the operation in d, the proteins were harvested and subjected to Western blotting.

[0316] Lipofectamine transfection of antisense oligonucleotides targeting E0771 cells TM The results of Western blotting after 3000 are shown in Figure 5: In this figure, after transfection with Lipofectamine TM 48 hours after 3000, add 5 μL of Lipofectamine to each well of the 12-well plate. TM 3000.

[0317] Table 1 Specific sequences of each ASO in Western blotting experiments

[0318] In Figure 5, antisense oligonucleotides designed for E0771 cells were transfected with Lipofectamine TM In the Western blot experiment results after 3000, the sequences of the antisense oligonucleotides represented by each band are shown in the table above.

[0319] Table 2 Sequence numbers corresponding to the specific sequences of each ASO

[0320] According to the results, the proteins represented by the sequences shown in bands B, D and E showed obvious inhibition results; and the proteins represented by the sequences shown in bands A, C, G, H, I, J and K also showed good inhibition results.

[0321] Optionally, the inhibitory RNA (eg, dsRNA) is chemically modified to enhance stability or other beneficial properties. The nucleic acids having the features of the present application can be synthesized and / or modified by methods well established in the art.

[0322] Alternatively, the inhibitory nucleic acid may include, for example, siRNA, shRNA, miRNA and / or miRNA, which are well known in the art and thus not described herein.

[0323] One skilled in the art will be able to readily assess whether siRNA, shRNA or miRNA effectively targets the downregulation of activity of the MALT1 tumor effector domain, for example, by transfecting the siRNA, shRNA or miRNA into cells and detecting the activity of the MALT1 tumor effector domain by Western blotting (detecting expression levels of the MALT1 tumor effector domain) or functional assays (e.g., activation of downstream targets of the MALT1 tumor effector domain, such as NF-κB signaling).

[0324] Correspondingly, the application of various substances capable of "inhibiting" target activity in the treatment of solid tumors according to Invention Point 1 is described.

[0325] Example 8

[0326] Further experiments were conducted on the mutant strains in Example 4 to explore the tumor immune escape mechanism, identify key sites, and determine the mechanism of action of MALT1.

[0327] For in situ injection of 1×10 5 E0771-VEC, E0771-Malt1 to uncleared (IgG group) or cleared CD8 + T cells (α-CD8 group) were expressed in the fat pads of mice. Tumors were measured twice a week. n = 12. The experimental results are shown in Figure 14.

[0328] Conditioned culture medium from E0771-VEC, E0771-Malt1, and E0771-Malt1-C461A cells was collected and used to treat bone marrow-derived macrophages (BMDM). Forty-eight hours later, the expression of MHC II and CD206 on BMDM was analyzed by flow cytometry. The flow cytometry results are shown in Figure 15.

[0329] Based on the mutations of each cell line, and combined with the correspondence between the target mutation cell lines and their cell numbers shown in Figure 9, the correspondence between the target mutation cell lines and tumor volume shown in Figure 14, and the flow cytometry experimental results of the macrophage transformation from M2 macrophages to M1 macrophages verified in Figure 15, it is shown that: the comparison of cell lines 2 and 7 with cell line 1 shows that the effect of MALT1 on macrophage proliferation is not dependent on Para-caspase activity; the comparison results of cell lines 4 and 5 with cell line 2, as well as the comparison results of cell lines 9 and 10 with cell line 7 show that once the key effector targets V87 and L88 sites discovered are mutated, the effect of MALT1 on macrophage proliferation immediately disappears.

[0330] Therefore, it can be determined that:

[0331] The key effector targets V87 and L88 discovered in the present invention are key sites for MALT1 to form a CBM complex. Mutation of any key amino acid can destroy the CBM complex, resulting in complete elimination of the effect of MALT1 on macrophages.

[0332] The above analysis identified V87 and L88 sites within the mouse MALT-1 tumor effector region as key sites for MALT1 to form the CBM complex. The study compared the abundance of MALT-1 protein expression in 11 cell lines before and after the addition of macrophages. The results, shown in Figure 7, demonstrate that mutations at V87 and L88 significantly reduce MALT1 protein expression after the addition of macrophages, as shown in the red box in Figure 7.

[0333] We further designed the effects of target knockout on solid tumors:

[0334] B16F10-MALT1-KD cells (melanoma cells) were supplemented with VEC, M-WT, M-WT-C83A, M-WT-V87R, M-WT-L88D, and M-WT-E104R (respectively marked from top to bottom on the right side of FIG16 ) to obtain the corresponding cell lines, and then 1×10 5 The corresponding cells were subcutaneously injected into the subcutaneous tissue near the groin of wild-type mice, and tumors were measured twice a week starting on day 6. n = 6. Figure 16 shows the tumor size on day 18.

[0335] Right: E0771-MALT1-KD cells (breast cancer cells) were supplemented with VEC, M-WT, M-WT-C83A, M-WT-V87R, M-WT-L88D, and M-WT-E104R (marked from top to bottom on the right side of Figure 17 ) to obtain the corresponding cell lines, and then 1×10 5 The corresponding cells were orthotopically injected into the fat pad of wild-type mice, and tumors were measured twice a week starting from day 7. n = 12. Figure 17 shows the tumor size on day 19.

[0336] It can be seen that mutations at the V87 and L88 sites greatly reduce the tumor volume of melanoma and breast cancer.

[0337] Example 9

[0338] After extensive screening, an antisense oligonucleotide (ASO) that can effectively degrade MALT1 has been found. The preparation process and specific antisense oligonucleotide sequence are shown in Example 7.

[0339] The antisense oligonucleotide drug precursor (ASO24, whose nucleotide sequence is shown in SEQ ID No. 2) can significantly inhibit the further development of cancer cells: the effect is verified in breast cancer cells (E0771) as shown in Figure 18: the antisense oligonucleotide drug precursor has a good effect of inhibiting protein expression. The drug precursors represented by the sequences shown in bands B, D, and E have obvious inhibitory results on MALT1 expression, and the drug precursors represented by the sequences shown in bands A, C, G, H, I, J and K also show good inhibitory effects on MALT1 expression (the numbers, sequences and serial numbers of these bands are shown in Tables 1 and 2).

[0340] Example 10

[0341] Two shRNAs (sequences not shown) were used to knock down Malt1. After knockdown, the cells became very sensitive to CD8 T cell killing, and the cell survival rate decreased significantly. Two shRNAs were used to knock down Malt1, and the corresponding cell lines were injected subcutaneously into mice to monitor the changes in tumor volume. After knockdown, the cell growth rate was very slow. The specific experiment is as follows:

[0342] Melanoma cells (B16F10) verification effect

[0343] B16F10-CTRL, B16F10-MALT1-KD1, and B16F10-MALT1-KD2 were respectively + T cells were co-cultured with an effector-target ratio (E:T) of 1:1. Luciferase activity was measured 24 hours later to assess tumor cell survival. The results are shown in Figure 19A. 5Cells from the control group (B16F10-CTRL) and the MALT1 knockdown groups (B16F10-MALT1-KD1 and B16F10-MALT1-KD2) were subcutaneously injected into the subcutaneous tissue near the groin of C57BL6 / J mice. Tumors were measured starting on day 7 (n=14). Tumor volume change curves are shown in Figure 19B.

[0344] Colon cancer cell (MC38) verification effect

[0345] MC38-CTRL, MC38-MALT1-KD1, and MC38-MALT1-KD2 were respectively + T cells were co-cultured with an E:T ratio of 1:1. Luciferase activity was measured 24 hours later to assess tumor cell survival. The results are shown in Figure 20A. 5 Cells from the control group (MC38-CTRL) and the MALT1 knockdown groups (MC38-MALT1-KD1 and MC38-MALT1-KD2) were subcutaneously injected into the subcutaneous tissue near the inguinal region of C57BL6 / J mice. Tumors were measured starting on day 7 (n=14). The tumor volume change curve is shown in Figure 20B.

[0346] Example 11

[0347] Comparison of the effects of the present invention's ASOs (ASO24 and ASO25, whose nucleotide sequences are shown in SEQ ID No. 2 and 3, respectively) with existing MALT1 targeted drugs

[0348] The results of the cell survival rate verification of mouse breast cancer cells (E0771) are shown in Figures 21A and B. E0771 cells treated with ASO NT (nontarget control), ASO 24 or ASO 25 (nucleotide sequences are shown in SEQ ID NO. 2 and 3, respectively) showed a significant difference in CD8 + Survival rate in T cell killing system (-MΦ) and three-cell culture system (+MΦ). Tumor cells: macrophages: CD8 + The ratio of T cells was 1:2:2. n = 12, data are mean ± SD, and statistical analysis was performed using Student's t test. ** represents p < 0.01. E0771 cells treated with DMSO or a final concentration of 10 μg / mL MALT1 protease inhibitor (MI-2) showed a significant difference in CD8 + Survival rate in T cell killing system (-MΦ) and three-cell culture system (+MΦ). Tumor cells: macrophages: CD8 +The ratio of T cells was 1:2:2. n=5, data represent mean ± SD, statistical analysis was performed using Student's t test, ns represents no significant difference, ** represents p < 0.01. In the figure, NC: control; MI-2: MALT1-targeted drug targeting para-caspase; NT: control that does not target any sequence in the mouse genome, 24, 25: application of effective ASO precursors. Among them, MI-2 (Histone Methyltransferase inhibitor) is an existing MALT1-targeted drug that inhibits the Menin-MLL interaction and is an irreversible MALT1 inhibitor. The structural formula is as follows:

[0349] The results of the cell survival rate verification of mouse melanoma cells (B16F10) are shown in Figure 22A and B. B16F10 cells treated with ASO NT, ASO24 or ASO25 showed a significant difference in CD8 + Cell survival rate in T cell killing system (-MΦ) and three-cell culture system (+MΦ). Tumor cells: macrophages: CD8 + The ratio of T cells was 1:2:2. n = 6, data are mean ± SD, and statistical analysis was performed using Student's t test. ** represents p < 0.01. (d) B16F10 cells treated with DMSO or a final concentration of 10 μg / mL MALT1 protease inhibitor (MI-2) showed a significant difference in CD8 T cell proliferation and cell death. + Survival rate in T cell killing system (-MΦ) and three-cell culture system (+MΦ). Tumor cells: macrophages: CD8 + The T cell ratio was 1:2:2. n = 5. Data are mean ± SD. Statistical analysis was performed using the Student's t test. ns indicates no significant difference, and ** indicates p < 0.01. In the figure, NC: control; MI-2: MALT1-targeting paracaspase-targeting drug; NT: control without targeting any sequence in the mouse genome; 24, 25: administration of potent ASO precursors.

[0350] Therefore, the lower survival rate of cancer cells proves that this ASO drug has a more significant effect and outperforms the existing MALT1 targeted drugs. Compared with MI-2, the antisense oligonucleotide drug precursor has a lower tumor survival rate and a more significant effect.

[0351] Example 12

[0352] Based on intratumoral experimental data from various mouse breast cancer and melanoma models (dosing started after 7 days, once every 3 days), this example studies the comparative effects of an ASO prodrug (ASO24, whose sequence is shown in SEQ ID No. 2) with PD-1 / PD-L1 and the effects of their combination.

[0353] 1×10 5 E0771 cells were orthotopically injected into the fat pad of wild-type mice, and PD-1 antibody (BioXCell #BE0033, clone J43, the same below) was used for treatment alone, ASO alone, or PD-1 antibody and ASO combined treatment starting from day 7. For anti-PD-1 antibody treatment alone, intraperitoneal injection was started seven days after tumor transplantation, once a week, 3 mg / kg each time, and the control group was injected with DPBS. For MALT1 ASO treatment alone, Invitro 2000 was used according to the instructions. In vivo DNA transfection kits were used. Seven days after tumor implantation, 5 nmol of the ASO was injected intratumorally twice weekly. A control group received either the vehicle or the nontarget ASO. Combination therapy was performed with the designated two individual treatments. Tumor measurements were taken after dosing, with treatment occurring every three days. N = 12. Data are mean values. Statistical analysis was performed using two-way ANOVA. ** indicates p < 0.01. Results are shown in Table 3.

[0354] Table 3 Comparison of the efficacy of anti-PD-1 antibodies and ASO prodrugs and their combined use in the treatment of breast cancer (E0771 cells) Note: Tumor volume was measured using an electronic vernier caliper to measure length and width. Estimated volume = 0.5 × length × length × width

[0355] 1×10 5 B16F10 cells were subcutaneously injected into the subcutaneous tissue near the groin of wild-type mice. Treatment with PD-1 antibody alone, ASO alone, or a combination of PD-1 antibody and ASO was initiated starting on day 7. N = 10. Data represent mean values. Statistical analysis was performed using two-way ANOVA. ** indicates p < 0.01. Results are shown in Table 4.

[0356] Table 4 Comparison of the efficacy of anti-PD-1 antibodies and ASO prodrugs and their combined use in the treatment of melanoma (B16F10 cells) Note: Tumor volume was measured using an electronic vernier caliper to measure length and width. Estimated volume = 0.5 × length × length × width

[0357] 1×10 5PyMT-A cells were orthotopically injected into the fat pads of wild-type mice. Treatment with PD-1 antibody alone, ASO alone, or the combination of PD-1 antibody and ASO was initiated starting on day 7. N = 10. Data represent mean values. Statistical analysis was performed using two-way ANOVA. ns indicates no significant difference, and ** indicates p < 0.01. The results are shown in Table 5.

[0358] Table 5 Comparison of the efficacy of anti-PD-1 antibodies and ASO prodrugs and their combined use in the treatment of breast cancer (PyMT-A cells) Note: Tumor volume was measured using an electronic vernier caliper to measure length and width. Estimated volume = 0.5 × length × length × width

[0359] 2×10 5 4T1 cells were orthotopically injected into the fat pads of wild-type mice. Treatment with PD-1 antibody alone, ASO alone, or the combination of PD-1 antibody and ASO was initiated starting on day 7. N = 10. Data represent mean values. Statistical analysis was performed using two-way ANOVA. ns indicates no significant difference, and ** indicates p < 0.01. The results are shown in Table 6.

[0360] Table 6 Comparison of the efficacy of anti-PD-1 antibodies and ASO prodrugs and their combined use in the treatment of breast cancer cells (4T1 cells) Note: Tumor volume was measured using an electronic vernier caliper to measure length and width. Estimated volume = 0.5 × length × length × width

[0361] The data in Tables 3-6 show that PD-1 drugs have little effect in PyMT-A and 4T1 breast cancers, while ASOs have significant effects. Overall, ASOs outperform or are comparable to PD-1s. Combining ASOs with PD-1s demonstrated excellent efficacy in all four models, demonstrating a synergistic effect between ASOs and PD-1s.

[0362] Using systemic delivery data from various breast cancer and melanoma models in mice (dosing started after 7 days, once every 3 days), this example studies the effects of ASO prodrugs compared with PD-1 / PD-L1 and the effects of their combination.

[0363] The experimental procedure was similar to that of intratumoral administration of ASO24 to E0771 cells, except that ASO24 was delivered via the tail vein of mice using LNP-ASO.

[0364] Table 7 Comparison of the efficacy of anti-PD-1 antibody and ASO prodrug system delivery and combined use in the treatment of breast cancer (E0771 cells) Note: Tumor volume was measured using an electronic vernier caliper to measure length and width. Estimated volume = 0.5 × length × length × width

[0365] Table 8 Comparison of the efficacy of anti-PD-1 antibody and ASO prodrug system delivery and combined treatment of breast cancer cells (4T1 cells) Note: Tumor volume was measured using an electronic vernier caliper to measure length and width. Estimated volume = 0.5 × length × length × width

[0366] The data in Tables 7-8 demonstrate that, while systemically delivered, ASO24 had no effect on PD-1 agents in 4T1 breast cancer, the ASO demonstrated a significant effect. The ASO performed more effectively than the PD-1 agent, and the combination of the ASO and PD-1 agent demonstrated excellent efficacy in both models, demonstrating a synergistic effect between the ASO and PD-1 agents.

[0367] Example 13

[0368] To verify the therapeutic effect of ASO (ASO24, whose sequence is shown in SEQ ID No. 2) on solid cancers other than breast cancer and melanoma, animal models of lung cancer, liver cancer, and colorectal cancer were used to verify the combination of ASO and PD-1 / PD-L1.

[0369] Treatment regimen of PD-1 antibody and ASO combination in mouse lung cancer model:

[0370] Wild-type C57BL / 6J mice were inoculated near the groin with 10 μl of a mixture of lung cancer cells (containing 1×10 6 Cells / mouse) were used, and treatment began on day 7 after inoculation. PD-1 antibody (BioXCell #BE0033, clone J43) was administered intraperitoneally once weekly at a dose of 3 mg / kg. LNP-ASO was injected intravenously every other day at a dose of 50 μg. Mice were sacrificed on day 15. Tumor size was measured in five mice per experimental group, and the mean tumor size for each group was calculated. Controls administered with either PD-1 antibody or LNP-ASO alone, as well as blank controls, were also established. The administration procedure and dosage were the same as for the combined use of both.

[0371] Treatment regimen combining PD-1 antibody and ASO in mouse liver cancer model:

[0372] Wild-type BALB / c mice were inoculated with Hep53.4 liver cancer cells by subcutaneous injection near the groin, with a cell inoculation volume of 1×10 6Treatment began on day 7 after inoculation. PD-1 antibody (BioXCell #BE0033, clone J43) was administered intraperitoneally once weekly at a dose of 3 mg / kg. LNP-ASO was injected intravenously every other day at a dose of 50 μg. Mice were sacrificed on day 15. Tumor size was measured in five mice per experimental group, and the mean tumor size for each group was calculated. Controls receiving only PD-1 antibody or LNP-ASO, as well as blank controls, were also established.

[0373] Treatment regimen of PD-1 antibody and ASO combination in mouse colorectal cancer model:

[0374] BALB / c mice were subcutaneously inoculated with CT26 colorectal cancer cells at a cell density of 1×10 6 / Mouse, 3 weeks later, euthanized the mice, cut the tumor tissue blocks into 1mm×1mm×1mm, anesthetized the mice, and transplanted the tissue blocks in situ (sutured to the damaged serosal tissue of the cecum or inserted directly into the serosal membrane). Treatment began 2 weeks after transplantation. PD-1 antibody (BioXCell#BE0033, clone J43) was administered once a week at a dose of 3 mg / kg, and the injection method was intraperitoneal injection. LNP-ASO was injected into the tail vein once every other day at a dose of 50 μg. The experimental mice were sacrificed after 15 days, and 5 mice were included in each experimental group. The tumor size was detected, and the average tumor size of each group of mice was calculated. In addition, a control group and a blank control group were set up for the administration of only PD-1 antibody or LNP-ASO. The administration procedure and dosage were the same as those for the combination of the two.

[0375] Therapeutic regimen of PD-L1 antibody and ASO combination in mouse lung cancer model:

[0376] Wild-type C57BL / 6J mice were inoculated near the groin with 10 μl of a mixture of lung cancer cells (containing 1×10 6 cells / mouse), and treatment began on the 7th day after inoculation. PD-L1 antibody (BioXCell#:BE0101; Clone:10F.9G2) was administered once a week at a dose of 10 mg / kg, via intraperitoneal injection. LNP-ASO was injected into the tail vein every other day at a dose of 50 μg. The experimental mice were sacrificed after day 15, and 5 mice were included in each experimental group. The tumor size was measured, and the average tumor size of each group of mice was calculated. In addition, controls and blank controls were set up for administration of only PD-L1 antibody or LNP-ASO. The administration procedure and dosage were the same as those for the combination of the two.

[0377] Treatment regimen combining PD-L1 antibody and ASO in mouse liver cancer model:

[0378] Wild-type BALB / c mice were inoculated with Hep53.4 liver cancer cells by subcutaneous injection near the groin, with a cell inoculation volume of 1×10 6 Treatment began on day 7 after inoculation. PD-L1 antibody (BioXCell#:BE0101; Clone:10F.9G2) was administered intraperitoneally once weekly at a dose of 10 mg / kg. LNP-ASO was injected intravenously every other day at a dose of 50 μg. Mice were sacrificed on day 15. Tumor size was measured in five mice per experimental group, and the mean tumor size for each group was calculated. Controls administered with either PD-L1 antibody or LNP-ASO alone and blank controls were also included.

[0379] Treatment regimen of PD-L1 antibody and ASO combination in mouse colorectal cancer model:

[0380] BALB / c mice were subcutaneously inoculated with CT26 colorectal cancer cells at a cell density of 1×10 6 / Mouse, 3 weeks later, euthanized the mice, cut the tumor tissue blocks into 1mm×1mm×1mm, anesthetized the mice, and transplanted the tissue blocks in situ (sutured to the damaged serosal tissue of the cecum or inserted directly into the serosal membrane), and started treatment 2 weeks after transplantation. PD-L1 antibody (BioXCell#:BE0101; Clone:10F.9G2) was administered once a week at a dose of 10 mg / kg, and the injection method was intraperitoneal injection. LNP-ASO was injected into the tail vein once every other day at a dose of 50 μg. The experimental mice were killed after 15 days, and 5 mice were included in each experimental group. The tumor size was detected, and the average value of the tumor in each group of mice was calculated. In addition, a control group and a blank control group were set up for the administration of only PD-L1 antibody or LNP-ASO. The administration procedure and dosage were the same as those for the combination of the two.

[0381] The experimental results are summarized in Table 9.

[0382] Table 9 Therapeutic validation results of the combination of LNP-ASO and PD-1 antibody and PD-L1 antibody in animal models of lung cancer, liver cancer, and colorectal cancer Note: Tumor volume was measured using an electronic vernier caliper to measure length and width. Estimated volume = 0.5 × length × length × width

[0383] As can be seen from the data in Table 9, the ASO prodrug of the present invention has therapeutic effects on various solid cancer model animals. Compared with PD-1 antibodies / PD-L1 antibodies, its therapeutic effect is equivalent to or better. When used in combination with PD-1 antibodies / PD-L1 antibodies, the therapeutic effect is excellent, showing a significant synergistic effect.

[0384] The above description is merely a preferred embodiment of the present invention and does not constitute any form of limitation to the present invention. Although the present invention has been disclosed as a preferred embodiment as above, it is not intended to limit the present invention. Any technician familiar with this profession can make slight changes or modifications to equivalent embodiments of the methods and technical contents disclosed above without departing from the scope of the technical solution of the present invention. However, any simple modifications, equivalent changes and modifications made to the above embodiments based on the technical essence of the present invention without departing from the content of the technical solution of the present invention are still within the scope of the technical solution of the present invention.

Claims

1. A MALT1 tumor inhibitor, characterized in that The MALT1 tumor inhibitor can inhibit the expression of MALT1 gene or inactivate the function of MALT1 protein; The MALT1 tumor inhibitor is selected from a preparation that can affect the expression of the death domain of the MALT1 protein, a preparation that knocks out the death domain, a preparation that changes the structure of the death domain, or a preparation that degrades the death domain.

2. The MALT1 tumor inhibitor according to claim 1, characterized in that The MALT1 tumor inhibitor targets the interaction site between the proteins of MALT1 and BCL-10, thereby reducing or losing the binding ability of MALT1 to BCL-10.

3. The MALT1 tumor suppressor according to claim 2, characterized in that The MALT1 tumor inhibitor can also inhibit MALT1 enzyme activity.

4. The MALT1 tumor inhibitor according to claim 1, characterized in that The MALT1 tumor inhibitor acts on at least the 64th to 114th amino acid residues based on the MALT1 amino acid sequence shown in SEQ ID No. 1, or the nucleotide sequence encoding the same.

5. The MALT1 tumor inhibitor according to claim 4, characterized in that The MALT1 tumor inhibitor acts on at least the 81st and / or 82nd amino acid residue based on the MALT1 amino acid sequence shown in SEQ ID No. 1, or the corresponding codons in the nucleotide sequence encoding the same.

6. The MALT1 tumor suppressor according to claim 1, characterized in that The MALT1 tumor inhibitor includes an agent that inhibits, blocks or destroys the protein-protein interaction between MALT1 and BCL10.

7. The MALT1 tumor suppressor according to claim 6, characterized in that The agent for inhibiting, hindering or destroying the protein-protein interaction between MALT1 and BCL10 is selected from a covalent cross-linking agent that binds to the MALT1 death domain, a polyclonal antibody against the MALT1 death domain, or a monoclonal antibody against the MALT1 death domain, a small molecule inhibitor that inhibits the protein-protein interaction between MALT1 and BCL10, or an agent that point-mutates the binding site between the MALT-1 death domain and BCL10, or an agent that eliminates the binding site between the MALT-1 death domain and BCL10 by homologous recombination or gene editing; Preferably, the covalent cross-linker that binds to the MALT1 death domain is selected from antioxidants, nonsteroidal anti-inflammatory drugs (NSAIDs), natural compounds, proteasome inhibitors, IKK inhibitors, NF-κB-specific antisense oligonucleotides, or cell-penetrating peptides; Preferably, the antioxidant comprises alanolide, N-acetyl-cysteine ​​((N-acetyl-cysteine)NAC)); The nonsteroidal anti-inflammatory drugs (NSAIDs) include cyclooxygenase-2 (COX-2); The natural compounds include cymbopogon japonicus, curcumin, ursolic acid, and resveratrol; The proteasome inhibitors include proteasome inhibitor PS341 and melatonin; The IKK inhibitor tumor suppressor protein phosphatase PHLPP2; The cell-penetrating peptide includes a cell-penetrating peptide inhibitor SN50; Preferably, the mutator of the protein-protein interaction site between MALT1 and BCL10 includes: a reagent for point mutation of the 81st and / or 82nd amino acid residues in the death domain of MALT1, a CRISPR-Cas9 gene shearing reagent, and a reagent for homologous recombination of the protein-protein interaction site between MALT1 and BCL10.

8. The MALT1 tumor suppressor according to claim 1, characterized in that The MALT1 tumor inhibitor changes the microenvironment of tumor tissue, significantly reduces the number of macrophages in the tumor tissue, and transforms the macrophages in the tumor tissue from M2 to M1.

9. The MALT1 tumor suppressor according to claim 1, characterized in that The MALT1 tumor suppressor is an antisense oligonucleotide that inactivates MALT1.

10. The MALT1 tumor suppressor according to claim 9, characterized in that The nucleotide sequence of the antisense oligonucleotide is shown in any one of SEQ ID No. 2-6 and 8-12.

11. The MALT1 tumor suppressor according to claim 10, characterized in that The nucleotide sequence of the antisense oligonucleotide is shown in any one of SEQ ID No. 2-3.

12. The MALT1 tumor suppressor according to claim 9, characterized in that The antisense oligonucleotide is chemically modified; Preferably, the antisense oligonucleotide further comprises a modified internucleoside linkage; Preferably, the antisense oligonucleotide further comprises a modified sugar; Preferably, the antisense oligonucleotide further comprises a modified nucleobase.

13. The MALT1 tumor suppressor according to claim 9, characterized in that The antisense oligonucleotide is delivered by a drug delivery system.

14. The MALT1 tumor suppressor according to claim 1, characterized in that The MALT1 tumor inhibitor that degrades the MALT1 death domain is selected from agents of PROTAC, molecular glue, LYTAC, MoDE, ATAC, Apt-LYTAC, AbTAC, PROTAB, REULR, KineTAC, IFLD, ATTEC, AUTAC or AUTOTAC pathways.

15. A pharmaceutical composition for treating tumors, characterized in that: The pharmaceutical composition comprises an effective amount of the MALT1 tumor inhibitor according to any one of claims 1 to 14, and a pharmaceutically acceptable carrier.

16. The pharmaceutical composition according to claim 15, characterized in that The pharmaceutical composition further comprises a second drug.

17. The pharmaceutical composition according to claim 15, characterized in that The second drug is selected from an immune checkpoint inhibitor, a chemotherapeutic agent, or a MALT1 enzyme activity inhibitor; The MALT1 enzyme activity inhibitor is a small molecule inhibitor.

18. The pharmaceutical composition according to claim 17, characterized in that The immune checkpoint inhibitor is selected from PD-L1, PD-L2, PD-1, CTLA-4, TIM-3, LAG-3, VISTA or TIGIT inhibitors.

19. The pharmaceutical composition according to claim 17, characterized in that The chemotherapeutic agent is selected from alkylating agents, antimetabolites, antitumor antibiotics, plants, hormones, and other types of chemotherapeutic agents; Preferably: Alkylating agents include nimustine, carmustine, lomustine, cyclophosphamide, ifosfamide, or glyphosate mustard; Antimetabolites include doxiflurane, doceflurane, 5-fluorouracil, mercaptopurine, thioguanine, fluguanidine, fumaridine, gemcitabine, fluazifop, hydroxyurea, methotrexate, eufovir, or ancitabine; Antitumor antibiotics include actinomycin D, doxorubicin, daunorubicin, epirubicin, mitomycin, bleomycin, or pirarubicin; Anti-tumor animal and plant-based drugs include irinotecan, harringtonine, hydroxycamptothecin, vinorelbine, paclitaxel, taxotere, topotecan, vincristine, vindesine, vindesine, vinblastine, vinblastine, teniposide, etoposide, or elemene; Antineoplastic hormones include atamestane, anastrozole, aminoglutethimide, letrozole, formestane, medroxyprogesterone, tamoxifen, or breast cancer inhibitors; Other classes of chemotherapeutic agents include asparaginase, carboplatin, cisplatin, dacarbazine, oxaliplatin, eloxatin, coplatin, mitoxantrone, or procarbazine.

20. A pharmaceutical combination product, characterized in that The pharmaceutical combination product comprises an effective amount of the MALT1 tumor inhibitor according to any one of claims 1 to 14 and a second drug for simultaneous or sequential administration.

21. The pharmaceutical combination product according to claim 20, characterized in that The second drug is selected from an immune checkpoint inhibitor, or a chemotherapeutic agent.

22. The pharmaceutical combination product according to claim 21, characterized in that The immune checkpoint inhibitor is selected from PD-L1, PD-L2, PD-1, CTLA-4, TIM-3, LAG-3, VISTA or TIGIT inhibitors.

23. The pharmaceutical combination product according to claim 21, characterized in that The chemotherapeutic agent is selected from alkylating agents, antimetabolites, antitumor antibiotics, plants, hormones, and other types of chemotherapeutic agents; The alkylating agent is selected from nimustine, carmustine, lomustine, cyclophosphamide, ifosfamide, or glyphosate mustard; The antimetabolite is selected from doxiflurane, doceflurane, 5-fluorouracil, mercaptopurine, thioguanine, fluguanidine, fumaridine, gemcitabine, fluazifop, hydroxyurea, methotrexate, eufovir, or ancitabine; The antitumor antibiotic is selected from actinomycin D, doxorubicin, daunorubicin, epirubicin, mitomycin, bleomycin, or pirarubicin; The anti-tumor plant and animal component drug is selected from irinotecan, harringtonine, hydroxycamptothecin, vinorelbine, paclitaxel, taxotere, topotecan, vincristine, vindesine, vinblastine, vinblastine, teniposide, etoposide, or elemene; The anti-tumor hormone is selected from atamestane, anastrozole, aminoglutethimide, letrozole, formestane, medroxyprogesterone, tamoxifen, or breast cancer inhibitor; The other class of chemotherapeutic agents is selected from asparaginase, carboplatin, cisplatin, dacarbazine, oxaliplatin, eloxatin, coplatin, mitoxantrone, or procarbazine.

24. Use of the MALT1 tumor inhibitor according to any one of claims 1 to 14, or the pharmaceutical composition according to any one of claims 15 to 19, or the pharmaceutical combination product according to any one of claims 20 to 23 in the treatment of a disease, wherein the disease comprises a tumor.

25. The use according to claim 24, characterized in that Applicable diseases are solid tumors; The solid tumors include, but are not limited to, malignant tumors occurring in the lungs, pancreas, liver, digestive tract, reproductive system, etc., such as Hodgkin's lymphoma, non-Hodgkin's lymphoma, lung cancer, breast cancer (including triple-negative breast cancer), melanoma, ovarian cancer, gastric cancer, colon cancer, rectal cancer, etc. Cancer, liver cancer, pancreatic cancer, head and neck malignancies, urinary system malignancies, endometrial cancer, cervical cancer, osteosarcoma, chondrosarcoma, Ewing's sarcoma, thyroid cancer, hepatoblastoma, and Wilms' tumor.

26. The use according to claim 24, wherein the applicable subject is a mammal.

27. The use according to claim 26, wherein the subject is a human.

28. A method for treating a disease, characterized in that: The method targets the MALT1 death domain, the gene expressing it, or the protein-protein interaction site between MALT1 and BCL-10; the method includes inhibiting, knocking out, changing the structure, and degrading the MALT1 death domain, so that the ability of MALT1 and BCL-10 to form a complex is reduced or lost.

29. The method of claim 28, wherein: Use the MALT1 tumor inhibitor according to any one of claims 1 to 14, the pharmaceutical composition according to any one of claims 15 to 19, or the pharmaceutical combination product according to any one of claims 20 to 23 as a therapeutic drug.

30. The method of claim 28, wherein: The treatment method changes the microenvironment of tumor tissue, significantly reduces the number of macrophages in the tumor tissue, and transforms the macrophages from M2 type to M1 type.

31. The method of claim 28, wherein: The treatment method also includes use in combination with a tumor treatment method, the tumor treatment method including surgery, radiotherapy, chemotherapy, or immunotherapy; Preferably, the immunotherapy is selected from nonspecific immune stimulation, oncolytic virus therapy, adoptive cells and gene-modified immune cells, tumor vaccines, immune checkpoint monoclonal antibodies (PD1 / CLAT4) and T-cell-based immunotherapy; Nonspecific immune stimuli include interferons and interleukins; The oncolytic virus therapy utilizes genetically modified viruses (e.g., herpes simplex virus or other viruses) to target cancer cells for programmed cell death through immune response; The T cell-based immunotherapy is selected from CAR-T therapy, TCR-T therapy, TILs therapy, or CTL therapy; Preferably, the patient is administered a combination of the pharmaceutical composition described herein and CAR-T cells targeting the following substances: EGFR (epidermal growth factor receptor) on non-small cell lung cancer, epithelial cancer, glioma; EGFRvIII (variant III of epidermal growth factor receptor) on glioblastoma; HER2 (human epidermal growth factor receptor 2) on ovarian cancer, breast cancer, glioblastoma, colon cancer, osteosarcoma, medulloblastoma; MSLN (mesothelin) on mesothelioma, ovarian cancer, pancreatic adenocarcinoma; PSMA (prostate-specific membrane antigen) on prostate cancer; CEA (carcinoembryonic antigen) on pancreatic adenocarcinoma, breast cancer, colorectal epithelial cancer; GD2 (disialoganglioside 2) on neuroblastoma and melanoma; IL13Rα2 (interleukin-13Ra2) on glioma ; GPC3 (Glypican-3) on hepatocellular carcinoma; CAIX (Carbonic anhydrase IX) on renal cell carcinoma (RCC); L1-CAM (L1 cell adhesion molecule) on neuroblastoma, melanoma, ovarian adenocarcinoma; CA125 (Cancer Antigen 125, also known as MUC16) on epithelial ovarian cancer; CD133 (Cluster of Differentiation 133, also known as prominin-1) on glioblastoma, cholangiocarcinoma (CCA); FAP (Fibroblast Activation Protein) on malignant pleural mesothelioma (MPM); CTAG1B (Cancer / Testis Antigen 1B, also known as NY-ESO-1) on melanoma and ovarian cancer; MUC1 (Mucin 1) on seminal vesicle carcinoma; FR-α (Folic Acid Receptor-α) on ovarian cancer.

32. The method of claim 28, wherein: The disease includes a tumor, further a solid tumor; Preferably, the solid tumor includes but is not limited to malignant tumors occurring in the lung, pancreas, liver, digestive tract, reproductive system, etc., such as Hodgkin's lymphoma, non-Hodgkin's lymphoma, lung cancer, breast cancer (including triple-negative breast cancer), melanoma, ovarian cancer, gastric cancer, colon cancer, rectal cancer, liver cancer, pancreatic cancer, head and neck malignancies, urinary system malignancies, endometrial cancer, cervical cancer, osteosarcoma, chondrosarcoma, Ewing's sarcoma, thyroid cancer, hepatoblastoma, and nephroblastoma.

33. The method of claim 28, wherein: The subject of the treatment method is a mammal or a human.

34. A target, characterized in that The target is the interaction site between MALT1 and BCL-10 proteins, or a nucleotide sequence encoding the site.

35. The target according to claim 34, characterized in that The target is the 64th to 114th amino acid residues based on the MALT1 amino acid sequence shown in SEQ ID No. 1, or the nucleotide sequence encoding the same.

36. The target according to claim 35, characterized in that The target is the 81st and / or 82nd amino acid residue based on the MALT1 amino acid sequence shown in SEQ ID No. 1, or the corresponding codon on the nucleotide sequence encoding the same.

37. Use of the target according to any one of claims 34 to 36 in screening drugs, characterized in that: The drug for treating tumor acts on the target, and the drug includes an inhibitor of the protein binding between MALT1 and BCL-10.

Citation Information

Patent Citations

  • Application of MALT1 protease inhibitor in preparation of medicine for treating non-small cell lung cancer

    CN111686111A

  • Application of telaprevir in preparation of MALT1 inhibitor, medicine for resisting MALT1-dependent tumors and anti-tumor medicine

    CN114469952A

  • Modulation of MALT1 expression

    US20040110145A1